

**Next generation surgical meshes for drug delivery and tissue engineering applications:
materials, design and emerging manufacturing technologies**

*Francesca Corduas^{1,2}, Dimitrios A. Lamprou², Elena Mancuso*¹*


¹ Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus – Newtownabbey BT37 0QB, UK.

² School of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UK.

*Corresponding author: Dr Elena Mancuso (e.mancuso@ulster.ac.uk; tel. +44 28 9036 6408)

Keywords: 3D Printing; electrospinning; manufacturing technologies; biomaterials; drug delivery; surgical mesh implants.

Graphical Abstract



Abstract

Surgical meshes have been employed in the management of a variety of pathological conditions including hernia, pelvic floor dysfunctions, periodontal guided bone regeneration, wound healing, and more recently for breast plastic surgery after mastectomy. These common pathologies affect a wide portion of the worldwide population; therefore, an effective and enhanced treatment is crucial to ameliorate patients' living conditions both from a medical and aesthetic point of view. At present, non-absorbable synthetic polymers are the most widely used class of biomaterials for the manufacturing of mesh implants for hernia, pelvic floor dysfunctions and guided bone regeneration, with polypropylene and poly tetrafluoroethylene being the most common. Biological prostheses, such as surgical grafts, have been employed mainly for breast plastic surgery and wound healing applications. Despite the advantages of mesh implants to the treatment of these conditions, there are still many drawbacks, mainly related to the arising of a huge number of post-operative complications, among which infections is the most common. Developing a mesh that could appropriately integrate with the native tissue, promote its healing and constructive remodelling, is the key aim of ongoing research in the area of surgical mesh implants. To this end, the adoption of new biomaterials including absorbable and natural polymers, the use of drugs and advanced manufacturing technologies, such as 3D printing and electrospinning, are under investigation to [address](#) the previously mentioned challenges, and improve the outcomes of future clinical practice. The aim of this work is to review the key advantages and disadvantages related to the use of surgical meshes, the main issues characterising each clinical procedure, and the future directions in terms of both novel manufacturing technologies and latest regulatory considerations.

1. General introduction

Surgical mesh implants are generally defined as flexible and thin flat sheets [1] that are commonly used to provide additional support to a weakened tissue [2]. The first meshes used in clinical practice date back to [1950s](#) , when they were explored for the treatment of hernia conditions [3]. Meshes for hernia repair applications provided a tension free reinforcement for the injured tissue [4] that resulted in better outcomes both in terms of tissue integration and consequent repair [3]. Having noticed the improvements reported in the treatment of hernia, in 1970s meshes were introduced for the management of pelvic floor dysfunctions (PFDs), including pelvic organ prolapse (POP) and stress urinary incontinence (SUI), with the first urogynaecological mesh approved by the U.S. Food and Drug Administration (FDA) only twenty years ago [5].

The ability to provide mechanical support to weak tissues was subsequently exploited in other clinical fields. For instance, in 2001 meshes were introduced to expand the size of the reconstructive pocket

in breast reconstructive surgery after mastectomy [6]. Surgical meshes have also been used to create an isolated environment for tissue regeneration. Particularly, guided bone regeneration (GBR) membranes have been extensively used as an efficient method for the reconstruction of both structure and function of alveolar bone defects before dental implant placement. Through this approach, the membrane is used to cover the defect site and direct the growth of new bone while preventing the infiltration of connective tissue into the defected area [7]. GBR meshes need different features with respect to those employed in hernia repair, mainly osteoinduction, which is the ability to recruit mesenchymal stem cells (MSCs) and influence their differentiation into osteoblasts, and osteoconduction, which is the ability of the mesh to guide bone tissue formation [8]. Finally, the use of meshes in form of dressings for wound healing applications intended to create a “safe space” for the wound bed, acting as a barrier against the external environment, preventing bacterial contamination, absorbing exudates and keeping it clean [9].

Up to now, meshes have been produced mainly using non absorbable materials, especially for hernia and PFDs. They have been developed as an alternative to biological prostheses, aiming to overcome the limitations related to their use, such as the possibility to develop infections, unpredictable mechanical properties and the high risk associated with tissue harvesting procedures [3,5]. However, their employment is also linked to a vast number of post-operative complications, with infection being the most common one in hernia [3], PFDs [5], GBR [7] and breast reconstruction (BR) [10]. Other complications include the arising of chronic immune reaction and subsequent fibrotic process [11], and device mechanical failure. Especially concerning meshes employed in PFDs, several restrictions have been imposed on their use by FDA and by the National Health Service (NHS) in UK, due to the substantial amount of side effects related to their use. These issues, in turn led to an important decrease in the number of mesh-based surgical procedures (from 13,990 in 2008 to 7,245 in 2016 for SUI, and from 3,073 in 2008 to 2,680 in 2016 for POP) [12] and, in some countries, to their complete ban [13,14].

Therefore, many efforts have been made in the last years to improve meshes' performances, particularly in terms of antibacterial behaviour, material selection and manufacturing process. Aiming to mitigate the immune reaction and counteract infections, a wide range of antibacterial agents and drugs have also been investigated (e.g. antibiotics, metallic nanoparticles, natural antimicrobials, biomolecules) [15,16], as well as absorbable and naturally-derived materials (e.g. collagen, chitosan, alginate) [7,17]. Additionally, the lack of patient-specific solutions has led to the employment of new technologies [18] aiming to develop personalised devices and to improve the integration with the native tissue. The feasibility of additive manufacturing (AM) and electrospinning has been extensively studied to deal with the personalised manufacturing strategies for such applications. Their

exploitation could be promising to design patient-specific devices with reproducible geometrical features and increased biomimetic activity [19,20].

Some of the mentioned clinical conditions, although not life threatening, are very common into the worldwide population and can have a negative impact on patients' social life and psychology. Furthermore, the amount of money spent for the treatment of these pathologies is high. Specifically, in Europe the total expenditure for the management of PFDs is 10 billion euros [7,19], while around 6 million dollars and 15 million dollars are estimated to be invested in hernia and wound care devices respectively, by 2027 [21,22]. Up to now, for each clinical condition no ideal surgical mesh device exists, and despite the big number of commercially available products, they still suffer from several limitations [18]. Therefore, the aim of this review is to provide an overview on the use of novel materials, drugs and antimicrobial agents in combination with emergent technologies for the manufacturing of drug-eluting meshes. The need for mesh designs more compliant to patients' anatomy, in order to better integrate within the surrounding tissue and thus reduce the number of post-operative complications are then reviewed and discussed. Ultimately, insights about current regulatory considerations and the potential further research holds, in order to advance current clinical practice, are provided.

2. Clinical applications

According to the specific field of application as well as clinical need, meshes can be adopted by surgeons *via* different types of surgical procedures, and with the final aim to provide mechanical support, healing and tissue repair.

2.1 Hernia

From a clinical perspective, hernias are caused by the protrusion of internal organs out of the abdomen, mainly due to the presence of a weak spot or a hole into the surrounding connective and muscular tissue [2,23], and can be classified into two different groups according to the protrusion location. Groin hernias are located in the bottom half of the body [24]. They mainly affect the male population with an incidence between the 27% and 43% [25]. Ventral hernias are located in the superior half of the body [24], and many times, they are referred to us as incisional hernias, since occur as consequence of weaknesses developed after laparoscopic abdominal surgery [26]. The current treatment of hernia includes mesh-based surgery, with 91,673 operations performed in 2018 in UK [12]. The reference standard is the Lichtenstein open "tension-free" procedure [25]. Traditional surgical procedures consisted into the superimposition of tissues which were not normally overlapped, thus introducing undesirable tension [27]. Lichtenstein approach consists in the fixation of the mesh (via tissue glues, tacks, staples or stitches) onto the aponeurotic tissue after having made an incision above the defect, thus considerably decreasing the level of tension to which the tissue will

be subjected [24,27]. Unfortunately, Lichtenstein approach has been associated in 63% of the cases with the arising of chronic pain, thus affecting patients' quality of life. So recently, the laparoscopic approach (transabdominal preperitoneal (TAPP) and totally extraperitoneal (TEP)) has gained a lot of attention because it makes the surgery safer and less invasive [25] (Figure 1-A).

2.2 Pelvic floor dysfunctions

POP is due to the inability of the pelvic floor to support organs of the pelvic cavity (e.g. urethra, bladder, vagina, uterus, cervix and rectum) thus causing their descendance from their original position [28]. The weakening of the pelvic floor, which is more common in the elder population (post menopause women) [29,30], is also the main cause for the arising of SUI, which is characterised by the uncontrolled spillage of urine due to the failure of the sphincter muscle [31]. It has been reported that PFDs develop in the 17% of the female population. Specifically, up to 73% of women suffer from POP and more than the 40% is affected by SUI [30].

According to the specific prolapsed organ, PFDs can be grouped in four types [32]:

- Anterior prolapse, characterised by the bulging of the bladder into the front wall of the vagina.
- Uterine prolapse, in which the womb protrudes out of the vagina.
- Vaginal prolapse, caused by the sagging of the upper part of the vagina.
- Posterior prolapse, due to the protrusion of the bowel into the back wall of the vagina.

There are several ways in which POP and SUI could be managed, which include non-surgical and surgical treatments [28]. Non-surgical treatments include life-style changes, such as weight loss, pelvic floor exercises, hormone treatments and the application of pessaries [28,32]. Among the most common surgical procedures, anterior colporrhaphy or sacrospinous ligament fixation, can be carried out without the use of meshes [33]. Instead, sling surgery [34] (especially used in the treatment of SUI [31]) and sacrocolpopexy (both via open surgery or with a laparoscopic approach) require the use of a prosthesis in order to restore the normal positions of the organs. Sling surgery is performed by inserting a mid-ureteral sling/tape to provide additional support to the urethra. Sacrocolpopexy, instead, consist in the placement of a mesh from the sacrum to the vagina/uterus [35] (Figure 1-B). Currently, NHS advise to use vaginal meshes as last resort due to significative amount of post-operative complications, which include pain, nerves damages, and sexual problems among other issues [34]. Additionally, in some other countries, such as New Zealand and Australia, vaginal meshes have been completely banned and are no longer supplied [13,14]. The regulatory considerations on the use of vaginal surgical meshes will discussed in section 7.

2.3 Breast surgery

The mechanical support exerted by meshes have also been used by surgeons during BR after mastectomy. Mastectomy consists in the partial or complete removal of the breast aiming to eliminate cancer, especially in those cases in which tumour cells have spread throughout all that area. Due to the physical and psychological burden, very often surgeons suggest the possibility to have a reconstruction [36]. In the UK, reconstructive surgery is performed in the 60% of the cases [37]. It consists in putting a saline or silicone implant under the skin or the muscles of the chest (subcutaneous and submuscular approach respectively) [38,39]. Lately, prepectoral approach, [through which the mesh is sutured to the inferior margin of the major pectoralis muscle](#), has become really promising [since it allows to create a larger reconstructive fold](#), thus making the final implant more stable and comfortable [10,38] (Figure 1-C).

2.4 Periodontal surgery

Mesh implants have also been exploited to provide a growth support during periodontal surgery, helping in the restoration of periodontium or of the alveolar bone prior to dental implant insertion. Periodontium is a complex tissue whose primary aim is to anchor the tooth to the mandible. It interfaces on one side with the root cementum and on the other side with the alveolar bone, which is the main support for teeth and gingiva [40]. Periodontitis is a very common disease (half of the US population is affected [41]) characterised by the gradual destruction of periodontium, often resulting in tooth and alveolar bone loss, as well as gingiva recession [40]. There are several ways in which this condition can be managed, among which guided tissue regeneration (GTR) and GBR are of interest for this review. The main difference between the two approaches relates to the fact that GTR is primarily used to restore the function of periodontium while GBR is used to help the growth of the alveolar bone [16]. However, in both the cases, the surgical procedure consists in the sub-gingival placement of a membrane in the defect site aiming to provide an isolate environment for tissue growth and regeneration [16,42] (Figure 1-D).

2.5 Wound dressings

Meshes in form of dressings have been widely employed also in the treatment of wounds. Wound management has become crucial due to the high incidence of deaths every year caused by burns (almost 180,000 deaths per year) [43] and the frequent development of chronic leg ulcerations [44]. Chronic wounds may develop when the healing process fails to progress through its normal stages, [due to the presence of underlying pathologies, such as venous or arterial problems](#) [44,45], [and thus causing](#) an impairment in tissue regeneration and formation [46,47]. TIME (tissue, infection, moisture, edge) and TWA (triangle of wound assessment) approaches, which are based on the wound examinations, are very common practises in order to choose the clinical plan [45]. Current management approaches [rely on](#) wound debridement, infection prevention strategies, biological

therapies [45] and on the use of passive dressings such as gauzes [48]. However, these strategies are often non-specific and unable to address all the problems related to impaired wound healing, such as moisture and pressure control and exudates absorption. Also, the use of passive dressings frequently result in poor outcomes, mainly related to the arising of secondary trauma or their inability to provide an efficient barrier against the external environment [45,48]. All these issues have led to the development of new bioactive dressings, which could play an active role in the healing process, providing a moist environment in the wound site, allowing gas exchange, preventing infections and protecting the wound from the external space [9,49] (Figure 1-E).

Currently, a significative number of surgical meshes are available on the market. They are made of different materials and characterised by different levels of inflammatory response, tissue infiltration, biodegradation rate and stability. In Table 1 are reported some examples of meshes currently employed in clinical practice for the treatment of hernia, PFDs, BR, wound healing, GBR procedures, including details about their material composition and key properties.




Figure 1: Schematization of the use of surgical meshes. A left) Representation of hernia pathology, in which a small part of the intestine protrudes from the abdominal wall; A right) hernia treatment via placement of surgical mesh [23]. B left) Apical compartment prolapse in PFDs; B right) Sacrocolpopexy [29]. C) Implant and mesh positioning in BR [10]; D) GBR surgical mesh placement between the epithelium and the underlying bone defect [16]; E) Examples of hyaluronic acid-based wound dressings for wound healing applications [49].

Table 1: Commercially available meshes currently used in clinical practice

Clinical application	Commercial product	Material composition	Key properties	Manufacturer	References
Hernia	Prolene	PP	Non-absorbable, medium weight, monofilament, macroporous mesh. Good fibrovascular ingrowth, infections resistance, compliance. Visceral adhesion risk.	Ethicon	[3,18]
	Marlex	PP	Non-absorbable, medium weight, monofilament, macroporous mesh. High tensile strength but induce a strong inflammatory reaction.	Marlex	[3,18]
	Marsilene	PET	Non-absorbable, lightweight, multifilament, macroporous mesh. Low infection risk but could induce a severe immune reaction with a strong production of fibrotic tissue.	Ethicon	[3,18]
	Dual Mesh	ePTFE	Non-absorbable, heavyweight, multifilament, microporous mesh. Promote tissue ingrowth and reduce the risk of attachment. Possibility to develop infections.	Gore	[3,18]
	Dexon	PGA	Absorbable, multifilament mesh. Minimal inflammatory response, resistance to adhesion. Low mechanical stability due to degradation, high recurrence rate. Can be used also for PFDs.	Davis & Geck	[3,5,18]
	Vicryl	Polyglactin 910 (92% glycolide, 8% lactide)	Absorbable, multifilament, medium weight, microporous mesh. Mechanical stability up to 3 weeks. Significant inflammatory response and low mechanical properties on the long term. Can be also used in PFDs and BR.	Ethicon	[3,5,18,50]
	Poly lactide Mesh	Poly lactide (95% lactide, 5% glycolide)	Absorbable, multifilament, medium weight mesh. Improved mechanical properties up to 9 months, decreased seroma and connective tissue formation. Activation of foreign body granuloma and giant cells.	Ethicon	[18]
PFDs	Gynecare gynemesh	PP	Non-absorbable, monofilament, medium weight, macroporous mesh. Good mechanical properties, easy to cut in custom shape. Possible retraction, extrusion and dyspareunia.	Johnson & Johnson	[5,51]
	Upsilon™ Y-mesh	PP	Non-absorbable, y-shaped, monofilament, lightweight, macroporous mesh. Minimal contact with the vaginal tissue. Possibility to develop infections, adhesion, erosion, extrusion and inflammation.	Boston Scientific	[5,51,52]
	Gore-Tex®	ePTFE	Non-absorbable, multifilament, microporous mesh. Less inflammatory response and adhesion risk with respect to PP . Low level of tissue ingrowth, risk of erosion and high rejection rate. Can be also used in GBR.	Gore	[5,7,53]
Breast reconstructive surgery	TiLoop Bra	Titanised PP	Non-absorbable, monofilament lightweight mesh. Used in prepectoral reconstruction. Low risk of inflammation, scar formation and shrinkage.	Pfm medical	[50,54]
	TIGR® Matrix	Glycolide and trimethylene carbonate; lactide and trimethylene	Absorbable macroporous mesh with two type of filaments (fast and slow degrading). Mechanical support for up to 9 months. Fully degraded after 3 years. Can be also used for hernia repair.	Novus Scientific	[18,50,55]
Wound healing	Dermagraft®	Polyglactin	Absorbable dressing colonized with neonatal fibroblasts. Production of growth factors that enhance the healing process. Used in the treatment of diabetic foot ulcers. Absorbed in 3-4 weeks.	Organogenesis	[56–58]
	Transcyte®	Nylon and silicon	Neonatal fibroblasts embedded in the matrix and cultured for up to 6 weeks, aiming to produce extracellular matrix and growth factors. Enhanced healing process.	Advanced tissue science	[56,58]
GBR	Cytoflex® Ti-Enforced®	Titanium frame enclosed in two PTFE layers	Multilayers non-absorbable membrane. Shape maintenance and minimal graft movement during healing. Barrier function against bacteria and gingival tissue-derived cells. Could be used in treatment which last from 30 days and up to 6 months .	Unicare Biomedical	[7,59]
	Tefguard Guidor®	PLA	2 layers absorbable membrane, with different pore size at each layer. The external layer enhances soft tissue growth. The internal layer allows for nutrients and vascular supply while acting as barrier against gingival tissue entrance. Total resorption in up to 2 months.	Sunstar	[7,60]

	Bio-Gide®	Collagen	Bi-layered and absorbable membrane. No need for second surgery. Long term stability. Good tissue integration, bone formation and wound stabilization.	Geistlich Pharma	[61]
--	-----------	----------	-------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------	------

3. Mesh-related complications

The use of surgical meshes **could potentially** led to significant improvements in terms of clinical outcomes, **considering their ability to support cell growth and collagen production** [3]. Their use is still accompanied by several drawbacks, which are listed in Table 2 according to the different clinical application. The adverse events have been found to mainly relate to the material used, mesh design and manufacturing method.

One of the major issues is immune reaction. Even if materials used in biomedical applications are biocompatible, their presence inside the body always induces the activation of the immune system [3]. Foreign body reaction is a key point when talking about mesh implants, especially about hernia, PFDs and BR. A strong immune reaction could potentially lead to the formation of a fibrotic scar tissue around the implant and to its encapsulation [3,11]. In the case of hernia and PFDs an excessive production of fibrotic tissue may cause native tissue erosion with the subsequent extrusion (or migration) of the mesh [3,5]. Moreover, the formation of the fibrotic capsule is often linked to a reduction of the available mesh area, also known as mesh contraction [5,62]. Similarly, for breast reconstructive meshes the intense immune reaction may promote capsular contracture, which in turn could result in pain and breast deformation [63].

Infections are usually caused by infiltration of small bacteria (1-2 μm) within the pores of the implant [64]. Considering this, it is evident that pores' dimension plays **a role in** the success of a mesh. Pores should be big enough to also allow the entrance of immune cells [64]. Some of the most frequent infections that may occur during hernia [15], PFDs [64], BR [10] and wound healing [17] management are related to the presence of *S. Aureus*, *E. Coli*, or other gram-positive and gram negative bacteria. With particular regards to wound healing, this condition may develop due to the chronic state of inflammation of the wound that could make the tissue more prone to the entrance of bacteria and to biofilm formation (see Figure 2) [65,66], **thus making the use of dressings a valuable option to counteract it** [48]. *Porphyromonas gingivalis*, *Aggregatibacter actinomycetemcomitans*, and *Streptococcus mutans* infections may develop, instead, after the application of dental membranes [7].




Figure 2: Different stages for biofilm formation in chronic wounds [65].

The mechanical properties of the employed materials, as well as the meshes', could be the cause for a non-constructive integration of the device with the surrounding tissue. Using very stiff polymers could strongly affect the degree of flexibility and pliability of the final product [5]. Moreover, during the treatment of hernia and PFDs the insertion of a rigid mesh may cause stress shielding, a phenomenon characterized by the thinning and erosion of the native tissue, and caused by a biomechanical **mismatch** between the prosthesis's **mechanical properties** and **those of** the tissue [67,68]. Likewise, the use of very stiff meshes in GBR for dental applications could potentially lead to the perforation of the gingival tissue with consecutive mesh dehiscence and exposure [69]. On the other hand, **absorbable** polymers show some limitations as well. **Their degradation time not always matches the ingrowth rate of the new tissue, thus causing a** loss of mechanical stability **due to implant mechanical failure** [5,18].

Finally, traditionally employed manufacturing methods, such as knitting, allow the production of meshes with limited customizability and **with geometrical and mechanical features that make them unable to replicate the complex tissue environment and to conform to individual patient's anatomy** [18].

Considering all these issues, the need for new strategies to implement meshes production has become evident. The encapsulation of drugs, antibacterial agents or bioactive molecules within the implant could be really powerful to help in counteracting infections [15,17,41]. Additionally, a mesh made of the appropriate material, with a correct biomechanical behaviour and a proper design is paramount to ameliorate its inclusion within the body [41,70].

Table 2: Major complications commonly associated to the use of surgical meshes in clinical practice.

Clinical application	Complication(s)	Incidence (%)	Reference
<i>Hernia</i>	Seroma	3.3	[71]
	Hematoma	7.9	
	Infections	1.5	
	Recurrence	42-57	
	Pain	10-12	
<i>POP</i>	Erosion	35.1	[72]
	Pain	31.4	
	Infections	16.8	
	Dyspareunia	7.2	
	Perforation	5.8	
	Urinary problems	5.3	
	Shrinkage	2.8	
	Recurrence	2.1	
<i>SUI</i>	Pain	34.9	[72]
	Erosion	31.8	
	Infections	18.9	
	Urinary problems	16.0	
	Perforation	8.3	
	Recurrence	7.5	
	Dyspareunia	5.3	
	Vaginal scarring	1.6	
<i>Breast reconstructive surgery</i>	Infections	6.1	[73]
	Seroma	4.8	
	Hematoma	9.5	
	Infections	6.1	
	Capsule fibrosis	2.2	
<i>Wound healing</i>	Chronic infections due to biofilm formation	60	[74]
<i>GBR</i>	Soft tissue complications (dehiscence, exposure, infections, abscess)	18	[75]

4. Materials for surgical meshes

Biomaterials processed as 3D scaffolds are one of the main pillars in tissue engineering-based approach. Scaffold properties, in terms of biocompatibility, biodegradability and biomechanical behaviour, strictly depend on [its design, architecture, porosity and pore size, and on](#) the biomaterial(s) choice [76]. In this manuscript, materials will be categorized into synthetic and natural. A further distinction will take place for synthetic materials, since they can be divided into absorbable and non-absorbable. A summary of the materials currently used, as well as possible future choices, is provided in Table 3.

Table 3: Current and future materials for surgical meshes

Material	Derivation/ Source	Melting Temperature	Degradation rate	Advantages	Disadvantages	Clinical / Potential use	Reference
PP	Synthetic	130 °C- 171°C	Non degradable	Inert, biocompatible, favours tissue ingrowth, good mechanical properties	High inflammatory response, adhesion with the viscera, increased stiffness over time	Hernia repair, PFDs, BR	[5,18,77,78]
PTFE/ ePTFE	Synthetic	325°C	Non degradable	Inert, biologically stable, less inflammatory response and viscera adhesion, good mechanical properties	Poor tissue ingrowth, risk for tissue erosion, second surgery for removal	Hernia repair, PFDs, GBR	[5,7,18,42,79]
PET	Synthetic	243-260 °C	Non degradable	High cytocompatibility, strong tissue ingrowth, less inflammatory reaction	Tissue erosion, Chronic infections	Hernia repair, PFDs	[5,18,80]
Titanium	Synthetic	1668°C	Non degradable	High mechanical properties, tissue ingrowth, corrosion resistant, less prone to develop bacterial infections	Tissue perforation, second surgery	GBR, in form of coating for BR	[7,69,77,81]
PGA	Synthetic	220°C-230°C	1.5-3 months	Minimal inflammatory response, resistance to adhesion, do not require second surgery.	Loss of tensile strength after absorption, possible development of harmful oxidative species during polymer break down	Hernia repair, PFDs, GBR, BR	[5,7,18,50,82]
PLA	Synthetic	140°C-180°C	3-6 months	Good <i>in vivo</i> biocompatibility, tissue ingrowth, <i>in vitro</i> strength for up to 8 months, do not require second surgery.	Loss of tensile strength after absorption, possible development of harmful oxidative species during polymer break down	Hernia repair, PFDs, GBR	[5,7,35,82,83]
PLGA	Synthetic	240°C-280°C	1-6 months	Biocompatible, suitable for drug delivery, tunable degradation rate, FDA-approved, easy handling, do not require second surgery.	Loss of mechanical stability	Hernia repair, GBR, Wound healing	[7,18,82,84–86]
PCL	Synthetic	59°C-64°C	2-4 years	Biocompatible, FDA-approved, cost-effective, easy processability, long degradation rate, do not require second surgery.	Possible mismatch of physical and mechanical properties, poor antimicrobial properties	Hernia, PFDs, GBR, Wound healing	[7,8,18,19,56,87]
Collagen	Natural	30°C-36°C (denaturation)	depending on the type of collagen (1-10 months)	Biocompatible, biodegradable, able to enhance fibroblasts activity, do not require second surgery.	High cost, rapid swelling, fast degradation rate, fragile, poor exudate absorption.	Wound healing, GBR, hernia	[7,18,88–90]
Chitosan	Natural	30°C-100°C (processing temperature)	depending on the deacetylation degree (i.e. 60%, 36 days-80 days)	Biocompatible, biodegradable, antibacterial properties, suitable for drug delivery applications,	Low mechanical properties, limited solubility in organic solvents, short half-life, limited biostability.	Wound healing, hernia (as coating)	[15,88,91,92]
Alginate	Natural	60°C-80°C (processing temperature)	depending on the molecular weight (75% low molecular weight and 25% high molecular weight, ~ 40 days)	Biocompatible, biodegradable, enhance cells growth, haemostatic properties, water absorption abilities.	Rapid degradation, unpredictable dissolution profile, no hydration properties.	Wound healing, GBR (in combination with other polymers)	[7,88,93–95]

4.1 Non-absorbable synthetic materials

Up to now, non-absorbable synthetic materials are the gold standard for biomedical applications in which meshes are used to provide additional mechanical support to the tissue. This is mainly due to their durability and mechanical features. In fact, mechanical strength and relatively long degradation rates are desirable properties for this type of surgical meshes. High mechanical strength is crucial to properly sustain the tissue, while moderate degradation rates are needed in order to give time to cells to populate the scaffold, produce new tissue while exerting at the same time the requested mechanical properties [42,96].

According to Baylón *et al.*, mesh implants can be divided into three main material-based categories, with non-absorbable synthetic meshes falling in the first one (“first generation meshes”). Some of the polymers that belong to this category are polypropylene (PP), polyethylene terephthalate (PET) and non-expanded/expanded polytetrafluoroethylene (PTFE/ePTFE) [3]. These materials have been extensively employed in the management of hernia [3], PFDs [5], BR [50] and periodontal GBR [42], with PP being the gold standard in several of these application. Some example of non-absorbable commercially available mesh are Prolene (Ethicon, PP, hernia), Marlex (Bard, PP, hernia), Marsilene (Ethicon, PET, hernia), DualMesh (Gore, ePTFE and PTFE, hernia) [18], Gyenecare (GynemeshJ&J, PP, PFDs), Upsilon™ Y-mesh (Boston scientific, PP, PFDs) [5], Cytoflex® Tefguard (Unicare Biomedical, PTFE, GBR) [7], Gore-Tex® (Gore-Tex®, ePTFE, GBR, PFDs) [5,7].

Recently, thermoplastic polyurethane (TPU), which combines properties of thermoplastics and rubbers, have also gained attentions, especially in the treatment of PFDs [97] and breast implants [98] mainly because of its biocompatibility, flexibility, haemocompatibility and easy processability. Thanks to its mechanical properties, could be a good choice to potentially reduce mesh related complications [19].

Aside from polymers, the excellent mechanical features, light-weight properties and ability to withstand inflammations of titanium have been investigated to design meshes for hernia [99], BR [77] and GBR [69]. According to the categorization made by Baylón *et al.*, titanium-coated implants fall into “second generation meshes” category [3]. In a clinical trial by Eichler *et al.* the performances of TiLoop Bra/TiMesh® (pfm medical ag, Köln, Nordrhein-Westfalen, Germany), a titanium-coated PP mesh for BR applications, were compared with the commonly used acellular dermal matrix (ADM) by analysing their clinical outcomes and the respective arising of complication rates. The study did not show any significative difference between the two devices [77]. Moreover, titanium-coated PTFE meshes have been also used as dental membranes and thanks to their higher compressive strength, they resulted in better outcomes in respect of non-coated PTFE meshes [42].

Unfortunately, despite their optimal mechanical behaviour, the use of non-absorbable meshes is often accompanied by an excessive immune reaction that results in a non-constructive remodelling of the tissue [19], adhesion to the viscera, erosion, [5] infectious complications [100] and, in the case of periodontal GBR membranes, a second surgery for removal [42].

4.2 Absorbable synthetic materials

To overcome the problems related to the permanent presence of a mesh inside the body, absorbable synthetic polymers seemed to be a good choice. They could be used both as coatings, to ameliorate the interaction between the implant and the body and possibly confer antibacterial properties [101], but also as main mesh backbone, since they will eventually degrade, and **ideally** leaving behind a new and healthy piece of tissue [5].

Poly(lactide acid) (PLA) and poly(glycolide acid) (PGA), as well as **poly(lactic-co-glycolic acid) (PLGA)** that is the polymer obtained by their combination, have been widely used in many biomedical applications and for the formulation of drug delivery systems. PLGA demonstrated to be extremely suitable for tissue engineering and drug delivery applications thanks to its tunable degradation rate (that depends upon the molecular weight of the co-polymers), high biocompatibility, easy handling and FDA approval [84]. One of the main fields of application of these polymers is in wound healing, very often used in form of fibrous dressing (this will be further analysed in the next sections), but also in form of drug-loaded nanoparticles to be used as coating for wound mats. For example, Choipang *et al.* designed a polyvinyl alcohol (PVA) hydrogel coated with ciprofloxacin loaded PLGA nanoparticles to treat pressure ulcers. The authors performed drug releasing test, noticing a sustained release for up to 6 days with an initial burst release; they assessed the antibacterial activity against *S. Aureus* and *E. Coli* and cytotoxicity using dermal fibroblasts. At a PLGA/Ciprofloxacin nanoparticles concentration of 244 mg, **bacterial growth was reduced of ~99% in both bacterial colonies, also non-cytotoxic effects were observed** [85]. PGA, PLA and PLGA were also used in the design of hernia, PFDs, BR and GBR meshes. Some examples of available meshes are Dexon (Davis & Geck, PGA, hernia and PFDs) [5,18], Vicryl (Ethicon, Polyglactin 910 [92% glycolide, 8% lactide], hernia, PFDs and BR) [5,6,18], Poly(lactide mesh) (Ethicon, Poly(lactide [95% lactide, 5% glycolide], hernia) [18]; Guidor (Sunstar, PLA) and Cytoflex Resorb® (Unicare Biomedical, PLGA, GBR) [7].

Polycaprolactone (PCL) is an absorbable polymer whose features are very attractive in tissue engineering field, since it is biocompatible, biodegradable, it can be solubilized in a variety of solvents **for fabrication** (e.g. chloroform and tetrahydrofuran), is inexpensive and FDA-approved. It has a relatively low melting temperature, thus resulting in an easy processability through a wide range of manufacturing technologies whose required molten polymers (e.g. fused deposition modelling (FDM), 3D Printing or hot-melt extrusion (HME)) [19,87]. **Additionally**, PCL has **a long** degradation

rates due to the absence of [suitable](#) enzymes within the human body, thus slowing down the absorption process [87]. This makes PCL very good for drug delivery since it permit to better control the medication releasing process; moreover [it can be easily combined with other polymers](#) in order to obtain composites with very different properties ([e.g. faster degradation rates](#)) that could potentially fulfil the most different needs [19]. Despite this advantages, there are very few commercially available meshes made of PCL or composites of PCL (such as Vivosorb® (Polyganics), Poly-DL-Caprolactone [PDLLCL], used in GBR applications [7]), but many research groups are now investigating the possibility to produce surgical meshes and dressings by using it. For example, Ebersole *et al.* assessed the effectiveness of PCL nanofibrous meshes for hernia repair applications. They tested six different [electrospun](#) meshes obtained by varying PCL polymeric content and processing conditions (flow rate: 3.5 mL/h–10 mL/h), aiming to evaluate their morphology and mechanical behaviour and concluding that high PCL content ([12% w/v](#)) and low flow rates (4 mL/h, [6 mL/h](#)) was the most promising combination [102].

However, meshes based on absorbable polymeric materials have showed several issues, especially with regards to hernia and PFDs. In fact, due to polymer degradation, it is very likely that the use of these implants is accompanied by loss of tensile strength and subsequent mechanical failure [5]; additionally, [rapid](#) absorption rates could potentially lead to the formation of a very poor scar tissue [62].

4.3 Absorbable natural materials

Collagen, chitosan and alginate are among the most exploited natural-derived biomaterials. Collagen is an abundant structural protein present in the human body with the ability to enhance fibroblasts functions [88]. Chitosan is a substance derived from the deacetylation of chitin, present in fungi's exoskeleton. It naturally possesses antibacterial activity, promotes drainage, avoid the production of exudates and allows gas exchange [17,88]. Alginate is obtained from seaweed, it is highly absorbent and biodegradable [93]. These materials could be engineered to produce a wide range of biomedical devices, but very often are used in form of hydrogel and due to their high biocompatibility and ability to absorb liquids, they have been extensively employed in wound healing applications [45,88]. These three materials were also combined by Xie *et al.* to successfully create a composite seawater-resistant wound dressing, that showed an enhanced ability to promote the healing process while absorbing exudates, [facilitating platelet aggregation, clot formation, fibroblasts and endothelial cells migration](#), keeping a moist environment and protecting the wound [103]. Aside of wound healing applications, collagen's properties have also exploited in periodontal GBR [41]. For instance, BioMend® and BioMend® Extended™ are bovine-derived type I collagen membranes for GBR that have been developed by Zimmer Denta Inc [104].

To improve the integration of non-absorbable meshes within the body and to reduce the related side effects, in the last years natural materials have been also adopted as coating agents [101]. Collagen, chitosan, cellulose and other ECM components are among the most used [3,18]. The behaviour of a chitosan-coated PP meshes was investigated by Udpa *et al.* The authors observed a superior attachment of myoblasts with respect to fibroblasts, which led to the formation of a functional muscular tissue. Also, even if neutrophils were anyhow recruited, **they resulted to be inactive, leading to the arising of** a very gentle immune reaction [105].

Faulk *et al.* investigated the long-term *in vivo* (rat model) remodelling in response to the adoption of an ECM-coated PP mesh for hernia application, in terms of both biochemical and biomechanical feedbacks. Their results confirmed the efficacy of ECM-coating **in respect of un-coated devices**, particularly, at 14 days post implantation the macrophages response was mild and after 180 days collagen deposition was minimal [106].

4.4 Grafts

According to the Baylón classification, third generation meshes includes biologic prostheses also called grafts [3]. Biological prostheses are natural and highly biocompatible meshes that could be easily populated by cells and then degrade to leave new tissue [3]. Grafts can be divided into three categories according to their origin [18]: autografts (autologous pieces of tissue), allografts (human-derived cadaveric pieces of tissue) and xenografts (animal-derived pieces of tissues) [107]. Allograft and xenografts are obtained by dermis decellularization in order to **remove cells from the tissue**, leaving just the organized collagen architecture (**ECM**) and producing a structure that can be generally called ADM [10]. These types of matrices have been very often used in hernia [18], PFDs [108], BR [100] and wound healing applications [93] aiming to reach an integration level of the prosthesis with the native tissue with minimal or no negative response. Some of the most common source of ADM are rectus fascia, fascia lata [109], human dermis, porcine dermis and porcine small intestine submucosa (SIS) [3]. Aside from dermal substitutes, epidermal grafts have also been used for wound healing applications. While the use of ADM requires a pre-decellularization of the dermis, using epidermal substitutes requires keratinocytes expansion and cultivation [93]. Even if there are reported advantages related to the use of grafts, **such as rapid host revascularization and cell repopulation** [10], there are also several drawbacks, which include **limitations related to the donor site and tissue harvesting, and** post-surgery pain in the case of autografts, possibility to develop infections and **prion disease in the case of allografts and xenografts** [108,110].

5. Drug-eluting surgical mesh implants

Lately, drug-eluting implants have gained great attention due to the numerous advantages with respect to older ways of drug administration and diseases management. One of the most important advantages is the possibility to sustain and control the medication release for long periods without affecting the drug stability [111]. Due to different fields of applications of surgical meshes, the most suitable drugs to use may vary according to the specific disease. However, it could be possible to differentiate these drugs into antibiotics, antimicrobials agents and nature/biology-derived antibacterial molecules. Therefore, this section will cover a general overview of some of the most used drugs and antimicrobial agents for drug-eluting antibacterial meshes.

5.1 Antibiotics

Antibiotics have been extensively used for bacteria-specific treatment [112]. Rifampicin is a semi-synthetic antibiotic that exerts activity against a wide range of bacteria, among which *S. Aureus* [113]. It has been exploited with promising results by Reinbold *et al.* to prepare rifampicin-loaded PLGA microspheres to be used as coating for surgical mesh in hernia management. Meshes treated with the new coating material exerted a prolonged drug release profile (60 days) and an antibacterial activity which lasted 30 days [114]. Another class of antibiotics very often used is fluoroquinolones (e.g. ofloxacin, ciprofloxacin, levofloxacin), a broad-spectrum antibiotics active against gram-positive and gram-negative bacteria [115]. Guillaume *et al.* investigated the antibacterial behaviour of an ofloxacin/PCL coated PP mesh for soft tissue applications (hernia and PFDs). The device successfully achieved a sustained antibiotic release profile for up to 4 days with no burst release. Antibacterial tests carried on *E. Coli* resulted in a potent antibacterial activity, showing an inhibition zone diameter equal to 39 mm [116]. Metronidazole, instead, have been used to counteract periodontitis-related infections [16]. Another class of very used antibiotics exploited in GBR are tetracyclines (e.g. minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline)) since they exhibit an anti-inflammatory, antibacterial, anti-collagenase activity, as well as osteoclasts and metalloproteinase inhibition, which is important in bone regeneration applications [117]. In a study by Ma *et al.*, minocycline-loaded chitosan nanoparticles have been incorporated into a collagen/chitosan membrane to be used in GBR treatment. *In vitro* drug release tests showed that antibiotic release rate was sustained for up to 7 days, with an initial burst release. Antibacterial activity was assessed *in vitro* against *Porphyromonas Gingivalis* and *Fusobacterium Nucleatum*, observing a bacteriostatic rate of 95.3% and 92.1% respectively, and higher antibacterial potential with respect to antibiotic-free membranes. *In vitro* biocompatibility assay (using MC3T3-E1 osteoblasts and L929 fibroblasts) was proven. Finally, from the *in vivo* studies using a rat model, the membranes' ability to guide bone regeneration was observed, leading to the formation of new bone tissue after 4 weeks [118].

Other antibiotics include gentamicin, which has been adopted against staphylococcal infections, and vancomycin, used as an alternative to treat methicillin-resistant *Staphylococcus Aureus* (MRSA) [15]. Unfortunately, the increasing employment of antibiotics, has gradually led to the development of antibiotic resistance [112]. To enlarge their activity spectrum, multi-therapy, which consist in the administration of a combination of drugs, is a useful strategy [15]. However, there is still a strong call for new therapeutic approaches.

5.2 Antimicrobial agents

Metallic nanoparticles (MNPs) could be another solution to confer antibacterial properties to mesh implants. Their mechanism of action is still under investigation, but it is thought by the most that their antibacterial activity could potentially derive from a natural toxicity that arise from nanoparticle surface dissolution or oxidative stress via the production of reactive oxygen species (ROS) on the nanoparticles' surface [119]. The antibacterial behaviour of MNPs-loaded PCL wound dressing was investigated by Muwaffak *et al.*, whose assessed the efficacy of Silver-loaded (Ag-loaded), Zinc-loaded (Zn-loaded) and Copper-loaded (Cu-loaded) meshes, finding out a higher activity of Ag and Cu against *S. Aureus* [120]. Ions incorporation could be an additional advantage also for meshes intended for GBR procedures. In a review by Florjanski *et al.*, it has been reported that silica and titanium nanoparticles could enhance bone regeneration, while silver has the potential to exert good antimicrobial properties [117]. In fact, the effectiveness of Ag MNPs for GBR was also studied by Chen *et al.* which tested two different methods to perform Ag MNPs coating (sonication or sputtering) on collagen membranes in order to investigate their antimicrobial activity against *S. Aureus* and *P. Aeruginosa*, biocompatibility (with C3H101/2 mice embryonic MSC) and bioactivity. Sonication was found to be the most promising method to coat Ag since membranes obtained in this way showed the most promising results in comparison to sputtering, both in terms of antibacterial behaviour and cytotoxicity at a concentration of 1 mg/ml sonication coating. Additionally, for both the types of coating methods, superior osteogenic activity and *in vitro* anti-inflammatory behaviour were observed if compared with the uncoated membranes [121]. Ag was found to be affective also against other bacterial infections very common in periodontitis (*Aggregatibacter Actinomycetemcomitans* and *Porphyromonas Gingivalis*). In fact, in a study by Marques *et al.* membranes made of natural rubber latex (NRL) and Ag MNPs were developed with promising results in terms of antibacterial activity, cell viability and bone formation. *In vitro* tests were performed using human deciduous dental pulp-derived mesenchymal stem cells (CDLH1 line) on three different samples (negative control, NRL, and NRL-AgNP) showing the highest percentage of cell viability (98%) for NRL-AgNP membranes. Additionally, *in vivo* studies (*Rattus Norvegicus Albinus*) were carried on to further investigate the

device's cytocompatibility and tissue's immune reaction, demonstrating a reduced inflammation with respect to NRL membranes and GBR properties [122].

In addition to MNPs, antiseptics can be included in the category of antimicrobial agents. Among them, chlorhexidine (CHX) have been employed both in hernia and dental applications, thanks to its activity against gram-positive, gram-negative and anaerobic bacteria, showing promising results [123].

Pe´rez-Ko´hler *et al.* assessed the antibacterial potential of CHX-loaded PP mesh against *S. Aureus*, *S. Epidermis* and *E. Coli* for hernia repair applications. They developed a new coating material made of N,N-dimethyl-N-benzyl-N-(2- methacryloyloxyethyl) ammonium bromide and CHX (1 % w/w). The antibacterial activity, as well as drug release rate and cytotoxicity were tested. Slightly better antibacterial behaviour was observed against *S. Aureus* and *S. Epidermis* but, in general, no adhesion of bacteria was found onto these meshes. CHX release profile was found to be quicker in the first 5h and then slower and sustained up to 72h. AlamarBlue® assay showed no cytotoxicity, however a reduced fibroblasts metabolic activity was observed [123]. The efficacy of chlorhexidine as antibacterial agent in dental applications is well known. Inoue *et al.* produced a CHX-loaded periodontal membrane made of bacterial 2,3 dialdehyde cellulose and cyclodextrin, showing a prolonged release (even with a burst release at the beginning) and adequate activity against *S. Aureus*, *E. Coli* and *C. Albicans* [124]. However, MNPs, as well as antiseptics, may possess some drawbacks, such as toxicity [119] and possibility to develop allergic reactions [125].

5.3 Naturally-derived antimicrobial agents and biomolecules

In order to achieve a better integration of the mesh implant with the surrounding tissue and with less cytotoxic effects, biology/nature-based antimicrobial molecules are up-and-coming. Honey, essential oils, chitosan and plant-derived substances are just few examples, often employed in wound healing applications. For example, Wang *et al.* combined the antimicrobial features of chitosan and honey with gelatine, at different concentrations, in order to create a hydrogel to be used in the management of burns. Antibacterial assay showed that the best outcomes were obtained for the hydrogel composed by 0.5g of chitosan, 20g of honey and 20g of gelatine, with a bacterial growth inhibition rate equal to 100%. The synergistic activity of the employed substances contributed to create an acidic environment able to entrap and neutralize bacteria. Additionally, toxicological analysis and *in vivo* studies (rat model) demonstrated the hydrogel's higher wound closure percentage in respect of commercially available dressings (MEBO®) [126].

Mancuso *et al.*, developed a PCL fibrous antibacterial mesh for soft tissue application by layer-by-layer deposition of Manuka honey (see Figure 3). Results showed that the addition of Manuka honey to the formulation did not alter the physico-chemical properties of the scaffold and the layer-by-layer

functionalization allowed its controlled release from the PCL fibres. The implant showed good cytocompatibility and proliferation for fibroblasts (human telomerase reverse transcriptase immortalized fibroblasts from non-malignant myoma, healthy skin human fibroblasts) and endothelial cells (primary human umbilical vein endothelial cells), and a concentration-dependent antimicrobial activity against *S. Aureus*, *E. Coli* and *P.Aeruginosa* [127].

Another promising approach to ameliorate the interaction between the surgical device and the human body is to include growth factors within the implant. For example, bone morphogenetic protein (BMP) and platelets have been successfully used in the treatment of periodontitis [16]. In a clinical study by Jung *et al.* the performances of rhBMP-2-coated membranes were assessed in 11 patients after a 6 months period. Hystomorphometric analysis results showed 37% of newly formed bone at the treated site and 76% of mature lamellar bone [128]. Ansarizadeh *et al.* designed a new platelet-rich fibrin (A-PRF)-loaded scaffold made of chitosan and collagen. Mechanical properties, degradation rate, cell viability (using mouse bone marrow mesenchymal stem cells (MSCs)) and osteogenic activity were investigated. The authors modelled the young modulus, the degradation rate and cell viability as variables dependent upon chitosan, collagen and A-PRF concentration, using a polynomial equation. From the performed experiments and numerical simulation, the optimal membrane composition was found to be the one made of a chitosan/collagen weight ratio equal to 4 and a A-PRF concentration equal to 0.58 mg/ml [129]. In a study carried on by Wang *et al.* fibroblast growth factors (FGF) were grafted, via oxygen plasma treatment, onto the surface of a fibrous poly-L-lactic acid (PLLA) mesh. The device, to be used in PFDs treatment, showed improved biocompatibility, collagen deposition and cells attachment, and less inflammatory response compared to untreated PLLA. Also, grafting via plasma treatment did not alter its mechanical properties [130].




Figure 3: (A) Scanning electron microscopy (SEM) and (B) atomic force microscopy (AFM) images of LbL-functionalised PCL electrospun meshes by using Manuka honey (MH) as polyelectrolyte at different concentrations (1.5, 3, 6, and 12% w/v, respectively); adapted from Mancuso et al. [127]

6. Manufacturing

The encapsulation of antimicrobial agents and drugs is just one of the possible approaches that could be exploited in order to produce meshes with antibacterial properties. Another way of proceeding could be “simply” based on the correct selection of the material, as well as the choice of the most suitable mesh design (i.e. morphological properties) [15]. To be effective against infections, mesh implants should possess a pores’ dimension much larger than 75 μm (macroporous meshes), so that to allow the entrance of bacteria, as well as of immune cells [131]. Additionally, macroporous mesh implants have shown a better response in terms of scar formation, resulting in less production of non-functional fibrotic tissue with respect to meshes with small pores (microporous) [70].

Another aspect that should be considered is the weight or density of the employed mesh, since it could affect the final biomechanical behaviour. Based on the same raw material (i.e polypropylene), heavyweight meshes (density $> 90 \text{ g/m}^2$) have proven to be stiff and often microporous, on the other hand, lightweight meshes (density $< 50 \text{ g/m}^2$), are more flexible, while still exerting mechanical strength, and usually macroporous [3,18].

Finally, filaments types and their spatial organization could strongly influence the outcomes. It has been proven that multifilament meshes are more prone to develop bacterial infections and less responsive in terms of cellular ingrowth [108]. Moreover, it is well known in tissue engineering that fibres orientation is a factor that strongly influences the interactions between the native tissue and the implant [132].

In order to satisfy these requirements, in addition to material selection, the adoption of the most fitting manufacturing method is crucial to produce patient-specific mesh implants, with tailorable physicochemical and biomechanical properties. Among these technologies, electrospinning allows to manufacture fibrous architectures with very good ECM-mimicking abilities, as well as topical drug delivery systems (DDS) [133]. On the other hand, additive manufacturing (AM) could be successfully employed in meshes production to create customized drug-eluting devices with pre-determined and reproducible morphological features [134]. These manufacturing methods allow to overcome the widely reported limitations of traditional approaches, including knitted and woven techniques. Poor customisability and especially the inability to resemble the biomechanical properties of the native tissue have been the main drawbacks of knitted meshes. Additionally, the high number of post-operative complications arising from the use of knitted meshes is another limiting factor of this traditional method [3,18]. Therefore, new manufacturing approaches have been recently introduced, aiming to produce patient-specific custom devices with tailorable biomechanical as well as functional properties (i.e. antibacterial and/or bioactive potential). Table 4 provides an overview of the main materials, medications and manufacturing methods exploited to produce surgical meshes.

6.1 Electrospinning

Electrospinning is one of the most employed manufacturing techniques for the fabrication of drug loaded devices [135]. It exploits electrostatic forces to produce sub-micron fibres starting from polymeric solutions (solution electrospinning, see Figure 4-A) or melts (melts electrospinning, see Figure 4-B) [136].




Figure 4: Schematic representation of A) solution electrospinning and B) melt electrospinning set-up and C) collector types to influence fibres orientation.

A polymeric jet forced out of a syringe (spinneret) and towards a collector, thanks to the application of a voltage difference. Fibres are formed subsequently to solvent evaporation or cooling down of the melt [137]. To obtain the desired morphological features, in terms of fibres diameter and orientation, it is possible by altering process parameters (e.g. voltage, tip-to-collector distance, polymer feeding rate) and external parameters (e.g. polymeric solution physicochemical properties, ambient temperature and humidity) [138], but also by changing and designing new collectors (see Figure 4-C), which allow the opportunity to produce a wide range of different mesh architectures, including randomly oriented fibres, aligned flat fibres, aligned tubular fibres etc. [133].

Electrospinning has been extensively used in tissue engineering applications due to the ability to create very thin fibres and fibrous architectures that have proven to properly mimic ECM [139]. Additionally, electrospinning provides also an easy and effective way to encapsulate drugs and molecules within these architectures [133]. Drugs encapsulation can be performed in several ways, such as surface functionalization (e.g. coatings, layer-by-layer and grafting), blend, multiaxial and emulsion electrospinning. Coatings, layer-by-layer functionalization and grafting could be successfully employed to load bioactive molecules within the mesh. The main issue with these encapsulation methods is that they are often multiple steps procedures. Conversely, electrospinning allows for the direct inclusion of medications during the spinning process [133].

6.2 Blend electrospinning

Blend electrospinning consist in the solubilisation (or dispersion) of the bioactive molecules in the polymeric solution to spin [140]. Hall-barrientos *et al.*, carried on several studies about the interactions of electrospun drug-loaded polymeric meshes for hernia repair applications, testing PCL, PLA and collagen [139,141]. One of their studies provides comparison of PCL and PLA fibrous meshes and evaluation of the biological response and antibacterial activity. The authors tested two different drugs (Irgsan (IRG, triclosan) and Levofloxacin (Levo)) with several mesh combinations (PCL–drug, PCL–collagen–drug, PLA–drug and PLA–collagen–drug). The obtained results showed good outcomes for PLA and PCL meshes and minimal bacterial infection, with higher cells adhesion and proliferation for Levo-loaded PCL meshes. IRG-loaded meshes show a minimal, or even absent, cells attachment and viability [142]. In fact, many research groups are now carry on several studies about the safety of triclosan, which is suspected to be dangerous for human health [143].

Electrospun mats have been very widely adopted also in wound healing management, since they not only promote cells adhesion, but also allow gas exchange and fluid absorption. García-Salinas *et al.*, developed a PCL electrospun anti-inflammatory matrix loaded with essential oils (carvacrol (CAR), thymol (THY), tyrosol (TYR) and squalene (SQU)) for wound healing applications, finding that THY-loaded matrices showed the most effective behaviour against inflammations *in vitro* [20].

Even if blend electrospinning is a really easy way to load molecules into fibres, it has some disadvantages, which include possible denaturation of the bioactive substance in presence of solvents, but also a possible non-homogeneous drug distribution within the implant [140].

6.3 Multiaxial electrospinning

Multiaxial electrospinning can be used to reach a control over the medication release from the fibre [136]. It allows the production of core-sheath and hollow fibres by using a spinneret equipped with two (coaxial electrospinning) or three (triaxial electrospinning) concentric needles, through which is

possible to spin different polymeric solutions and drugs at the same time [144]. He *et al.*, designed a dual DDS periodontal membrane via coaxial electrospinning loaded with naringin (NAR), aiming to promote osteo-differentiation and bone growth, and metronidazole (MNA), to counteract infections. PLGA was used as sheath material to encapsulate MNA, while polyvinylpyrrolidone (PVP) was selected as core material to encapsulate NAR. The device showed an enhanced antibacterial activity **against *Fusobacterium Nucleatum* with respect to un-loaded fibres**, and stimulated cell growth [145]. Prado-Prone *et al.* also employed coaxial electrospinning for the development of antibacterial wound mat made of PCL (core) and loaded with Zn nanoparticles (ZnNPS) (shell) (Figure 5). Antibacterial tests were carried on against *S. Aureus* and *E. Coli*, observing a major activity against gram-positive (*S. Aureus*) bacteria. The effects of UVA light exposure (prior to bacteria inoculation) **on mats** were studied too, resulting in an even more effective antibacterial activity [146]. Hansesn *et al.*, also tested the performances of coaxial fibres against solid fibres (obtained by blend electrospinning) for PFDs applications. In this study, the performances of PCL hollow and solid fibres, loaded with FGF, connective tissue growth factors (CTGF) and rat mesenchymal stem cells (rMSC) was investigated *in vivo* by using a rat model. The results highlighted **the inability of hollow fibres to provide mechanical support during collagen deposition, due to their fast degradation. In fact, among all the tested meshes, these ones were associated with the highest level of complications (first of all herniation)** [147].




Figure 5: Zn-loaded PCL coaxial fibres developed by Prado-Prone *et al.* and their mechanism of action [146].

6.4 Emulsion electrospinning

Core-shell fibres can be produced by spinning an emulsion rather than a solution [148]. The use of the correct solvents is crucial in both emulsion and multi-axial electrospinning due to the necessity to spin more solutions at the same time. Solvents that do not cause their mutual precipitation are needed, so a good choice could be exploiting immiscible solutions [149]. To stabilize these solutions, the employment of surfactants could be useful [144,150], however their presence may alter the mechanical properties of the final device [151] as well as its adhesion properties [144]. Mangir *et al.* loaded L-ascorbic acid (AA) and Ascorbate-2-Phosphate (A2P), which have been proven to increase collagen production, into PLA electrospun fibres using emulsion electrospinning. Their aim was to assess any improvements in terms of collagen production and its impact on mechanical properties of the device. The developed mesh actually enhanced collagen production, with slightly better results for A2P releasing mesh, but the mechanical properties were affected by the inclusion of surfactants [151].

All the mentioned techniques are solution-based as all employed polymeric solutions. An important point to consider when using solution-based electrospinning techniques is the toxicity of most solvents used in the process (e.g. chloroform, tetrahydrofuran, dimethylformamide). Using solvent-free configurations, such as melt electro-writing (see section 6.8) could be a valuable option [152].

6.5 Additive manufacturing

AM technologies are based on the layer-by-layer building up of the final structure starting from digital data. This information can be obtained through a computer tomography (CT) or magnetic resonance (MRI) and can be subsequently elaborated in order to generate a digital design file by means of computer aided design (CAD) software, thus allowing the creation of complex 3D architectures with predictable geometric features (e.g. pore volume, interconnectivity and distribution) [153,154] (see Figure 6) [155]. It has become very attractive in the biomedical field due to its cost-effectiveness, possibility to obtain personalized devices in relatively fast times and to process both composites and biomaterials.

Selective laser sintering (SLS) and stereolithography (SLA) are light-based AM techniques that have been used often in the biomedical field. In SLS, a laser beam is selectively directed on a powder bed to fuse a thin layer of them in the desired shape. The process is repeated layer by layer, and after hardening of the melted powders, a defined 3D structure is obtained. Similarly, SLA, uses light to harden photo sensitive polymers and built 3D objects after a layered repetition of the same process. Even if SLS and SLA proved to be successful in producing biomedical devices, they also present some drawbacks, among which there are high processing temperatures and costs for SLS [156,157] and a small number of biocompatible photo polymers for SLA [158]. On the other hand, 3D printing

is another promising AM technology that have been successfully employed to include bioactive compounds and cells directly during printing (see section 6.7) [134,159].




Figure 6: Additively manufactured surgical meshes workflow: from patient data to clinical application.

6.6 Hot melt extrusion (HME) and fused deposition modelling (FDM)

HME is based on the extrusion of a polymeric melt, which is forced through a die by means of convey screws, to form a fibre [160]. This technique have been used in pharmaceuticals to include drugs within a polymeric carrier [19]. Additionally, HME was the first method employed to produce polymeric meshes, in which filaments, once extruded, were knitted according to a specific pattern [3]. Hot melt extruded drug-loaded fibres could also be used as feeding polymer during the printing of implants *via* FDM (See Figure 7) [161]. FDM is based on the CAD-controlled layered extrusion of molten polymer fibres [158]. It gained attention because of its ability to print devices with good dimensional precision and quality, while maintaining low cost and reduced times of production [162].




Figure 7: Patient-specific wound dressings; A) Filaments loaded with metals, from left to right: plain PCL, Ag (10% w/w)-PCL, Zn (10% w/w)-PCL, Zn (25% w/w)-PCL, Cu (10% w/w)-PCL and Cu (25% w/w)-PCL; B) 3D printed Cu-PCL nose dressing; C) Release profiles of Ag (10% w/w)-PCL, Cu (10% w/w)-PCL, Cu (25% w/w)-PCL, Zn (10% w/w)-PCL and Zn (25% w/w)-PCL in PBS (adapted from Muwaffak et al.) [120].

Domínguez-Robles *et al.* used HME and FDM to produce Levo-loaded TPU filaments that were subsequently employed in 3D printing of meshes for PFDs as shown in Figure 8. The research group studied the mechanical behaviour of the devices, as well as their antibacterial activity. The final data has proven to be more flexible and less rigid in respect of PP meshes, but also, to be effective against *S. Aureus* and *E. Coli* [97].




Figure 8: PFD mesh developed by Domínguez-Robles *et al.* A) CAD project with relative mesh dimension; B) flexibility of TPU meshes; C) Levo-loaded TPU meshes; D) SEM images of Levo-loaded TPU vaginal meshes [97].

FDM was also used by Qamar *et al.* to produce ciprofloxacin-impregnated meshes for hernia repair. Two types of material were processed (PP and PVA) and meshes were printed with different pore geometries (diamond and square) and dimensions. Their mechanical behaviour, antibacterial activity and *in vivo* biocompatibility were investigated using a rabbit model. Drug was released in both meshes for almost 7 hours, with an initial burst release. Considering that for hernia repair applications a tensile strength between 16 N/cm² and 30 N/cm² is required, PVA meshes showed a better biomechanical behaviour compared with PP, since the obtained tensile strength ranged between 17 N/cm² and 30 N/cm². Additionally, it was observed a greater biocompatibility of PVA devices in respect of PP, with less fibrous tissue and mild immune reaction [163].

Baek *et al.* used FDM and electrospinning to produce a hybrid PCL scaffold for BR, aiming to improve implant-tissue interactions. The device showed enhanced flexibility with respect to ADM. Furthermore, it induced lipogenic differentiation without any foreign body reaction, thus resulting very promising for BR surgery management [164].

A multi head deposition system was used to combine and print at 135°C a blend of PCL, PLGA and β-tricalcium phosphate (β-TCP) to prepare a dome-shaped 3D membrane for periodontal applications. In a study by Shim *et al.*, meshes were subjected to tensile test and *in vitro* cell proliferation test, *in vivo* (beagle dog model) clinical setting and were also compared to titanium membrane used in clinics, proving their equal efficacy in terms of bone formation and osseointegration. The results could open the horizon to new frontiers in the use of biodegradable membranes, thus avoiding second surgery [165].

Due to the high processing temperatures required, only a limited number of polymers (e.g. thermoplastic polymers as TPU and PCL) [134] and drugs can be used to create biomedical implants and devices via FDM [158]

6.7 3D bioprinting

Extrusion-based 3D bioprinting received a great attention in tissue engineering because of the possibility to print a wide range of polymeric-based biomaterials, with or without cells, called bio-inks, and often loaded with bioactive compounds [159]. A 3D bioprinter is generally composed by a dispenser (mechanically or pneumatically driven) which is connected to a robotic stage that can move along the three axes (x,y,z), laying down the bio-ink onto a collecting plane, as shown in Figure 9 [162].




Figure 9: Schematization of material extrusion during 3D bioprinting: A) pneumatically-driven; B-C) mechanically-driven [159].

One promising field of application of 3D bioprinting is wound healing. For example, with the intension to recreate the by-layered structure of the skin, Wang *et al.* combined high voltage printing and 3D bioprinting to design a bi-layered membrane scaffold made of PLGA and alginate in which PLGA was used as the superior layer to mimic the epidermis, while alginate was used as the inferior layer to mimic the dermis. The obtained implant provided a moist and insulated environment for the wound. Additionally, it successfully acted as barrier against *S. Aureus*, it showed good biocompatibility (with murine L929 cells) and it accelerated wound healing *in vivo* (rat model, complete healing in 12 days), promoting an initial and constructive inflammation, and stimulating vascularization and collagen deposition [166]. Another device was developed by Afghah *et al.*, whose included silver nitrate particles in the formulation to provide antibacterial effects to the dressing. They printed a PCL-block-poly (1,3-propylene succinate) (PCL-PPSu) mats and investigated its degradation rate and hydrophilicity. Moreover, *in vitro* cytotoxicity assays using human dermal

fibroblasts and antibacterial tests against *S. Aureus*, *C. Albicans*, *E. Coli*, *P. Aeruginosa* were carried on. The obtained results made it clear that at a concentration of 1% wt/wt of silver nitrate, the dressing's antibacterial behaviour was significantly enhanced, especially against *E. Coli* and *C. Albicans*. Also, the inclusion of silver nitrate in the formulation did not alter the cytocompatibility of the used materials [167].

3D bioprinting has greatly evolved towards the production of complex scaffolds, however it still has some limitations such as low printing speed and needs for complex bio-inks and multi-material architectures. In fact, even considering all the progress done within the bioprinting field, re-creating biological structures can be difficult, since tissues and organs possess way more complicated architectures, with different mechanical properties, sizes as well composition at the cellular level [159].

6.8 Melt electro-writing (MEW)

MEW is a manufacturing technology that combined working principles from electrospinning and AM. MEW exploit voltage differences to “write” electrospun scaffolds with pre-determined architecture and geometrical features (Figure 10) [133].

However, there is a substantial difference between solution-based electrospinning and MEW. Electrospinning requires the arising of fluids instabilities (whipping instability) to draw the fluid out of the spinneret and towards the collector. When on the other hand, MEW based on the concept according to which the application of an electric field between the nozzle and the collector, stabilizes the jet, avoiding instabilities. This allows to continuously lay down polymeric filaments with different diameter by using low flow rates and just one nozzle [168]. Aside from the electric field, some other parameters must be tuned in order to achieve a controlled and reproducible flow. The feeding rate to the spinneret should match the one of the stabilized polymer jet in order to avoid fibre pulsing, which can cause an unstable flight path. Also, the velocity of the moving collector (the spinneret is fixed) should be higher than the speed of the jet. This velocity is called critical translation speed (CTS): when operating above its value, fibres could potentially reach sub-micron sizes. However, in this condition non-linear fluid patterns may arise. Thus, the majority of MEW-produced scaffolds possess fibres with a diameter that ranges between 2µm and 50µm [168,169].




Figure 10: Examples of different patterns and scaffolds that can be obtained via MEW (Scale bars = 100 μm A–D, 500 μm E–H, 50 μm I, 200 μm J–L, and 100 μm M–P) [169].

MEW could be preferred in respect of solution-based electrospinning, since it allows to produce better fibres both in terms of morphology and drug delivery mechanism (no burst release) [137]. However, it presents some limitations that are mainly due to high processing temperatures, that limits the number of materials and drugs which can be used [137].

Despite its disadvantages, MEW was used by Hewitt *et al.* to produce a melt electrospun PCL scaffold loaded with milk proteins (MPs) to be used in wound healing applications. Their aim was to assess the feasibility of the manufacturing process and investigate *in vitro* scaffold's performances ([wound healing assay](#)). The authors, were able to write PCL/MPs powders blend at a temperature of 85°C and obtain good results in terms of both protein release ([up to 21 days](#)) and tissue regeneration [170].

Dubey *et al.* used PCL in the development of a reinforced membrane for GBR. PCL was melt-electrospun and then covered with a layer of [Gelatin-Methacryloyl \(GelMA\)](#) and amorphous magnesium phosphate (AMP). [The authors assessed the physico-chemical and biomechanical properties of the device, and its *in vivo* \(rat model\) performances.](#) The results showed that the reinforced membrane possessed high stiffness (can be modulated by altering the chemical composition of the mesh), high rate of mineralization, osteogenic gene expression and *in vivo* bone formation. Moreover, the presence of the layer of GelMa and AMP, reduced the *in vivo* degradability of the implant [171]. Finally, MEW was combined with 3D bioprinting to manufacture a melt electrospun PCL mesh for PFDs applications. In a study by Paul *et al.*, meshes produced using MEW were covered with a layer of 3D bioprinted aloe Vera/alginate (AV/ALG) hydrogel loaded with endometrial mesenchymal stem cells (eMSCs) in order to enhance the antibacterial and anti-inflammatory behaviour of the construct. Thanks to the improved *in vivo* compatibility and tissue integration, this implant could be successfully employed to treat POP by also using autologous eMSCs from the patient [172].

Table 4: Summary table of the main materials, drugs and manufacturing methods employed in the production of meshes for hernia, PFDs, GBR, wound healing and BR surgery.

Application	Materials	Drugs	Manufacturing methods	References
Hernia	<ul style="list-style-type: none"> • <u>Non-absorbable Polymers</u> PP, PET, PTFE/ePTFE • <u>Absorbable Polymers</u> PLGA, PGA, Polyglactin, Polylactide, PCL, PLA, PVA • <u>Natural Materials</u> ADM, Chitosan • <u>Others</u> Titanium 	<ul style="list-style-type: none"> • <u>Antibiotics</u> Rifampicin, Fluoroquinolone (Ofloxacin, Levofloxacin), Ciprofloxacin, Gentamicin, Vancomycin • <u>Antiseptics</u> Chlorhexidine, Triclosan 	Blend electrospinning, FDM, HME	[3,18,99,105, 114,116,123, 142,163],
PFDs	<ul style="list-style-type: none"> • <u>Non-absorbable Polymers</u> PP, PET, ePTFE, TPU • <u>Absorbable Polymers</u> PLLA, PGA, Polyglactin, PLA • <u>Natural Materials</u> ADM, Chitosan, Alginate, Others, Aloe Vera 	<ul style="list-style-type: none"> • <u>Antibiotics</u> Levofloxacin, Ofloxacin • <u>Biomolecules</u> FGF, CTGF, Ascorbic acid 	Blend electrospinning, Coaxial electrospinning, Emulsion electrospinning, HME, FDM, MEW, 3D bioprinting	[5,19,97,105, 108,116,130, 147,151,172]
GBR	<ul style="list-style-type: none"> • <u>Non-absorbable Polymers</u> PTFE/ePTFE • <u>Absorbable Polymers</u> PLA, PDLCL, PLGA, PDLLA, PLGA, PVP, PCL • <u>Natural Materials</u> Bacterial cellulose and cyclodextrin, Collagen, GelMA • <u>Others</u> Titanium 	<ul style="list-style-type: none"> • <u>Antibiotics</u> Metronidazole • <u>Antiseptics</u> Chlorhexidine • <u>Antibacterial agents</u> Ag MNPs • <u>Natural antibacterial</u> B-TCP, AMP, Naringin 	Coaxial electrospinning, Extrusion-based 3D bioprinting, MEW	[7,16,42,69,104,124,145,165,171,173]
Wound healing	<ul style="list-style-type: none"> • <u>Absorbable Polymers</u> PVA, PLGA, PCL • <u>Natural Materials</u> Collagen, Alginate, Chitosan 	<ul style="list-style-type: none"> • <u>Antibiotics</u> Ciprofloxacin • <u>Antibacterial agents</u> MNPs (Ag, Zn, Cu) • <u>Natural antibacterial</u> Essential oils, Honey, Milk proteins 	Blend electrospinning, Coaxial electrospinning, High voltage printing, 3D bioprinting, MEW	[45,85,88,120,126,146,166,167,170,174]
BR	<ul style="list-style-type: none"> • <u>Non-absorbable Polymers</u> PP, TPU • <u>Absorbable Polymers</u> Polyglactin, Glycolide and trimethylene carbonate, PCL • <u>Natural Materials</u> ADM • <u>Others</u> Titanium 	-	FDM, Electrospinning	[6,50,77,98,100,164]

7. Regulatory Considerations

Due to the high number of post-operative complications, the use of vaginal meshes for the treatment of POP and SUI was reviewed by FDA [175]. The process started in 2011 with a discussion about the effectiveness and safety of these devices [176] and resulted in the withdrawal of some products from the market in 2019 [175].

Recently, new regulations have been adopted by the European Parliament as well as FDA, according to which surgical vaginal meshes have been reclassified from class II to class III (high risk) medical devices [177]. PFDs meshes have been discontinued in some countries, such as Australia and New Zealand [13,14] and, as indicated by the National Institute for Health and Care Excellence (NICE), they should be adopted only as last resort, making patients aware of all the possible complications [178]. The use of meshes for the treatment of POP is still on-going in the UK, although new regulations have been put in place by the Medicines and Healthcare products Regulatory Agency (MHRA). These include a tight post-marketing surveillance of the implants, which is based on the recording of any mesh-related adverse events, *via* Yellow Card Scheme, as well as the introduction of a periodic summary update reports (PSUR) [179]. Different considerations can be made for graft-derived slings for SUI surgery, since they are still considered as a treatment option in many countries. Specifically, slings derived from autologous or heterologous tissues are actually preferred in comparison to vaginal meshes because of the abundance of positive data collected following their use [34,180] and limited recorded issues post implantation.

Meshes for hernia have been also subjected to some investigations in order to evaluate their safety and feasibility. In a Cochrane review about the outcomes of groin hernia repair with and without meshes, the superiority of mesh-based treatments in comparison to traditional surgery ([in terms of recurrence rate, complication rates, duration of the surgery and post-operative recovery](#)) was concluded [181]. Moreover, in 2019 a review from the Welsh Chief Medical Officer confirmed the safety and the employability of hernia meshes [12]. Regardless, and given the controversial data derived from the use of meshes for PFDs, FDA is continuing specific investigations about the use of hernia meshes, monitoring the outcomes of all the marketed devices and encouraging patients to report any kind of adverse event *via* MedWatch, which is the FDA Safety Information and Adverse Event Reporting program [182]. Regarding the use of meshes for BR surgery, FDA has started to pay attention also on these type of meshes, although currently there are no regulations in place since more data are needed to establish their feasibility and safety [1].

Wound dressings are subjected to some regulations too, however these are less restrictive in comparison to those for vaginal and hernia meshes. These guidelines mainly regard honey and silver antimicrobial dressings [183]. Honey dressings must not be used on patients with an extreme

sensitivity to honey and bee product in general, and should be employed very carefully in diabetic patients [184]. Silver dressings must be used only in case of evident bacterial infection and to treat complicated wounds. Also, due to the possible toxicity of silver [185], they should not be used on acute wounds, on children, during pregnancy and on patients with hepatic or renal impairment [186]. Finally, some important considerations must be done on the manufacturing methods, especially on 3D printing. This kind of manufacturing process has gained great consideration during the last decade and has been successfully used by surgeons to treat some life-threatening conditions. In light of this, FDA is currently working on the definition of guidelines for 3D printed devices, in order to ensure their safety for usage in clinical practice [187]. In 2017, the U.S. Department of Health and Human Services, the FDA, the Centre for Devices and Radiological Health and the Centre for Biologics Evaluation and Research drafted a document with some manufacturing and testing considerations to be followed during the production of a 3D printed medical devices, which included:

- precise identification of process conditions (including environmental factors) and production workflow;
- information about materials, employed computer aided design (CAD) software, employed machine, product design, post-processing conditions;
- process validation, i.e. process reproducibility;
- in case of personalized devices, information about patients' clinical parameters, imaging techniques and images' quality, and any changes applied to pre-existed devices and manufacturing process must be documented [188].

The guidelines listed above have been provided to manufacturers as recommendations for device design, manufacturing and testing [189]; however, FDA is still working on more accurate regulations for AM processed and 3D-printed medical devices.

8. Conclusion and future directions

The employment of surgical meshes in clinical practice has revolutionized the way to approach some specific health conditions. Before the use of meshes, sutures were the main solution to manage hernia defects [190] and PFDs [35]. Passive dressings, such as gauzes, were mainly used to treat chronic wounds [48]. Implant muscles' coverage was the only choice in BR [38]. Periodontitis treatment mainly relied on the control of infection and disease progression [42]. **Unfortunately**, due to the high number of side effects and post-operative complications, the use of meshes in clinical practice is currently controversial and subjected to several limitations. Particularly, despite mesh implants employed in hernia repair are generally considered safe, they are still under careful observation [2], while those used in PFDs have been banned and/or are subjected to tight and strict regulations [177].

Membranes used in GBR are unable to properly mimic the complex structure of the periodontium and more insights are required to assess the long-term stability of the regenerated bone tissue [42]. Additionally, further improvements are needed to design smart drug-eluting wound dressings [48] with a competitive cost [45]. Moreover, despite the interesting and promising field of application of meshes for BR, little is known about their use, and with very limited research studies available.

As highlighted in the current review paper, most of the cited studies are at first experimental stages, proving that more tests must be carried out in order to prove *in vivo* feasibility of mesh implants. Moreover, human experimentation seems to be still far for some of these devices. However, the potential that mesh technology holds is high, especially considering the paucity of alternative treatments for [these pathologies](#) [5]. So, addressing the existing challenges is crucial.

[Despite the steps forward made in the design of antibacterial meshes, a better understanding of the complex tissue-device interactions is needed in order to propose new strategies aiming to modulate the immune reaction and infections and to achieve a better biomechanical compatibility \[191\]. To this end, exploiting the use of 3D bioprinting and MEW, in order to manufacture multi-material and/or multi-architectural devices, might be a promising approach to move forward and thus develop future implant with patient-specific and tailorable properties. Additionally, with the purpose to improve device bio-integration and tissue-mimicking ability, efforts should be placed in finding new combinations of antibacterial agents, biomolecules and cells to be loaded into surgical meshes. Even though we are still far from the ideal mesh implant, the promise of the latest literature can certainly be considered an interesting starting point for future developments in this field.](#)

Author Contributions

Miss F. Corduas: Literature search, Writing - original draft; Dr D. Lamprou: Writing – Reviewing & Editing, Supervision, Resources; Dr E. Mancuso: Writing – Reviewing & Editing, Supervision, Resources.

ACKNOWLEDGMENT

The authors would like to thank Ulster University for the Ph.D. scholarship to Miss Francesca Corduas.

Compliance with ethics guidelines

The authors declare that they have no conflict of interest.

This study does not contain any studies with human or animal subjects performed by any of the authors.

References

- [1] Breast Implant Surgery, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/breast-implants/breast-implant-surgery> (accessed June 7, 2020).
- [2] Hernia Surgical Mesh Implants, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/implants-and-prosthetics/hernia-surgical-mesh-implants> (accessed June 7, 2020).
- [3] K. Baylón, P. Rodríguez-Camarillo, A. Elías-Zúñiga, J. Díaz-Elizondo, R. Gilkerson, K. Lozano, Past, Present and Future of Surgical Meshes: A Review, *Membranes*. 7 (2017) 47. <https://doi.org/10.3390/membranes7030047>.
- [4] M. Hammoud, J. Gerken, Inguinal Hernia, in: *StatPearls*, StatPearls Publishing, Treasure Island (FL), 2020: pp. 1–6. <http://www.ncbi.nlm.nih.gov/books/NBK513332/> (accessed June 7, 2020).
- [5] E. Mancuso, C. Downey, E. Doxford-Hook, M.G. Bryant, P. Culmer, The use of polymeric meshes for pelvic organ prolapse: Current concepts, challenges, and future perspectives, *J Biomed Mater Res*. 108 (2019) 771–789. <https://doi.org/10.1002/jbm.b.34432>.
- [6] R. Rolph, J. Farhadi, The use of meshes and matrices in breast reconstruction, *Br J Hosp Med*. 79 (2018) 454–459. <https://doi.org/10.12968/hmed.2018.79.8.454>.
- [7] R. Ia, S. Gs, F. Ae, G. Cj, S. Sh, E. Ja, G. Ms, B. Gl, Barrier membranes for dental applications: A review and sweet advancement in membrane developments, *Mouth Teeth*. 2 (2018). <https://doi.org/10.15761/MTJ.1000108>.
- [8] P. Gentile, V. Chiono, C. Tonda-Turo, A.M. Ferreira, G. Ciardelli, Polymeric membranes for guided bone regeneration, *Biotechnology Journal*. 6 (2011) 1187–1197. <https://doi.org/10.1002/biot.201100294>.
- [9] K. Vowden, P. Vowden, Wound dressings: principles and practice, *Surgery (Oxford)*. 35 (2017) 489–494. <https://doi.org/10.1016/j.mpsur.2017.06.005>.
- [10] H. Logan Ellis, O. Asaolu, V. Nebo, A. Kasem, Biological and synthetic mesh use in breast reconstructive surgery: a literature review, *World Journal of Surgical Oncology*. 14 (2016) 1–9. <https://doi.org/10.1186/s12957-016-0874-9>.
- [11] G. Gigliobianco, S. Roman Regueros, N.I. Osman, J. Bissoli, A.J. Bullock, C.R. Chapple, S. MacNeil, Biomaterials for Pelvic Floor Reconstructive Surgery: How Can We Do Better?, *BioMed Research International*. 2015 (2015) 1–20. <https://doi.org/10.1155/2015/968087>.
- [12] Barber S., *Surgical mesh implants*, (2019).
- [13] Urogynaecological Surgical Mesh Implants, Medsafe., Medsafe. (n.d.). <https://www.medsafe.govt.nz/hot/alerts/UrogynaecologicaSurgicalMeshImplants.asp> (accessed July 3, 2020).
- [14] Transvaginal (urogynaecological) surgical mesh, Therapeutic Goods Administration., Therapeutic Goods Administration (TGA). (2019). <https://www.tga.gov.au/hubs/transvaginal-mesh> (accessed July 3, 2020).
- [15] O. Guillaume, R. Pérez-Tanoira, R. Fortelny, H. Redl, T.F. Moriarty, R.G. Richards, D. Eglin, A. Petter Puchner, Infections associated with mesh repairs of abdominal wall hernias: Are antimicrobial biomaterials the longed-for solution?, *Biomaterials*. 167 (2018) 15–31. <https://doi.org/10.1016/j.biomaterials.2018.03.017>.
- [16] M.C. Bottino, V. Thomas, G. Schmidt, Y.K. Vohra, T.-M.G. Chu, M.J. Kowolik, G.M. Janowski, Recent advances in the development of GTR/GBR membranes for periodontal regeneration—A materials perspective, *Dental Materials*. 28 (2012) 703–721. <https://doi.org/10.1016/j.dental.2012.04.022>.
- [17] M.E. Okur, I.D. Karantas, Z. Şenyiğit, N. Üstündağ Okur, P.I. Sifaka, Recent trends on wound management: New therapeutic choices based on polymeric carriers, *Asian Journal of Pharmaceutical Sciences*. (2020) 1–24. <https://doi.org/10.1016/j.ajps.2019.11.008>.

- [18] S. Kalaba, E. Gerhard, J.S. Winder, E.M. Pauli, R.S. Haluck, J. Yang, Design strategies and applications of biomaterials and devices for Hernia repair, *Bioactive Materials*. 1 (2016) 2–17. <https://doi.org/10.1016/j.bioactmat.2016.05.002>.
- [19] Z.-L. Farmer, J. Domínguez-Robles, C. Mancinelli, E. Larrañeta, D.A. Lamprou, Urogynecological surgical mesh implants: new trends in materials, manufacturing and therapeutic approaches, *International Journal of Pharmaceutics*. 58 (2020) 119512. <https://doi.org/10.1016/j.ijpharm.2020.119512>.
- [20] M. Abrigo, S.L. McArthur, P. Kingshott, Electrospun Nanofibers as Dressings for Chronic Wound Care: Advances, Challenges, and Future Prospects: Electrospun Nanofibers as Dressings for Chronic Wound Care ..., *Macromol. Biosci*. 14 (2014) 772–792. <https://doi.org/10.1002/mabi.201300561>.
- [21] Hernia Repair Devices and Consumables Market Growth - 2027, Allied Market Research, Allied Market Research. (n.d.). <https://www.alliedmarketresearch.com/hernia-repair-devices-market> (accessed October 2, 2020).
- [22] Advanced Wound Care Market Size & Growth Analysis by 2027, Allied Market Research, Allied Market Research. (n.d.). <https://www.alliedmarketresearch.com/advanced-wound-care-market> (accessed October 2, 2020).
- [23] Z. Mikołajczyk, A. Walkowska, Design methodology of the strength properties of medical knitted meshes, *IOP Conf. Ser.: Mater. Sci. Eng.* 141 (2016) 012012. <https://doi.org/10.1088/1757-899X/141/1/012012>.
- [24] C. Wang See, T. Kim, D. Zhu, Hernia Mesh and Hernia Repair: A Review, *Engineered Regeneration*. 1 (2020) 19–33. <https://doi.org/10.1016/j.engreg.2020.05.002>.
- [25] N.L. Bullen, L.H. Massey, S.A. Antoniou, N.J. Smart, R.H. Fortelny, Open versus laparoscopic mesh repair of primary unilateral uncomplicated inguinal hernia: a systematic review with meta-analysis and trial sequential analysis, *Hernia*. 23 (2019) 461–472. <https://doi.org/10.1007/s10029-019-01989-7>.
- [26] Krause, L., Ventral Hernia: Risk Factors, Causes, and Symptoms, Healthline., Healthline. (2015). <https://www.healthline.com/health/ventral-hernia> (accessed July 6, 2020).
- [27] P.K. Amid, Alex.G. Shulman, I.L. Lichtenstein, The Lichtenstein open “tension-free” mesh repair of inguinal Hernias, *Surg Today*. 25 (1995) 619–625. <https://doi.org/10.1007/BF00311436>.
- [28] Pelvic Organ Prolapse (POP), U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/urogynecologic-surgical-mesh-implants/pelvic-organ-prolapse-pop> (accessed July 3, 2020).
- [29] J. Pizarro-Berdichevsky, M.M. Clifton, H.B. Goldman, Evaluation and Management of Pelvic Organ Prolapse in Elderly Women, *Clinics in Geriatric Medicine*. 31 (2015) 507–521. <https://doi.org/10.1016/j.cger.2015.06.008>.
- [30] M.M. Good, E.R. Solomon, Pelvic Floor Disorders, *Obstetrics and Gynecology Clinics of North America*. 46 (2019) 527–540. <https://doi.org/10.1016/j.ogc.2019.04.010>.
- [31] Stress Urinary Incontinence (SUI), U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/urogynecologic-surgical-mesh-implants/stress-urinary-incontinence-sui> (accessed July 6, 2020).
- [32] Pelvic organ prolapse, National Health Service., National Health Service. (2017). <https://www.nhs.uk/conditions/pelvic-organ-prolapse/> (accessed July 3, 2020).
- [33] M. Cervigni, F. Natale, A comprehensive view on the actual trend in pelvic organ prolapse repair, *Abdom Imaging*. 38 (2013) 884–893. <https://doi.org/10.1007/s00261-012-9960-9>.
- [34] Surgery and procedures for urinary incontinence, National Health Service., National Health Service. (2017). <https://www.nhs.uk/conditions/urinary-incontinence/surgery/> (accessed July 3, 2020).
- [35] E. Mironska, C. Chapple, S. MacNeil, Recent advances in pelvic floor repair, *F1000Res*. 8 (2019) 1–11. <https://doi.org/10.12688/f1000research.15046.1>.

- [36] Mastectomy, National Health Service., National Health Service. (2017). <https://www.nhs.uk/conditions/mastectomy/> (accessed July 3, 2020).
- [37] R. Vidya, F.M. Iqbal, A Guide to Prepectoral Breast Reconstruction: A New Dimension to Implant-based Breast Reconstruction, *Clinical Breast Cancer*. 17 (2017) 266–271. <https://doi.org/10.1016/j.clbc.2016.11.009>.
- [38] S.-E. Kim, Prepectoral breast reconstruction, *Yeungnam Univ J Med*. 36 (2019) 201–207. <https://doi.org/10.12701/yujm.2019.00283>.
- [39] Breast Reconstruction After Mastectomy, National Cancer Institute., National Cancer Institute. (2016). <https://www.cancer.gov/types/breast/reconstruction-fact-sheet> (accessed July 3, 2020).
- [40] A. Nanci, D.D. Bosshardt, Structure of periodontal tissues in health and disease*, *Periodontol* 2000. 40 (2006) 11–28. <https://doi.org/10.1111/j.1600-0757.2005.00141.x>.
- [41] Z. Sheikh, N. Hamdan, Y. Ikeda, M. Grynypas, B. Ganss, M. Glogauer, Natural graft tissues and synthetic biomaterials for periodontal and alveolar bone reconstructive applications: a review, *Biomater Res*. 21 (2017) 1–20. <https://doi.org/10.1186/s40824-017-0095-5>.
- [42] Y. Liang, X. Luan, X. Liu, Recent advances in periodontal regeneration: A biomaterial perspective, *Bioactive Materials*. 5 (2020) 297–308. <https://doi.org/10.1016/j.bioactmat.2020.02.012>.
- [43] Burns, World Health Organization., World Health Organization. (n.d.). <https://www.who.int/news-room/fact-sheets/detail/burns> (accessed June 9, 2020).
- [44] M. Gohel, Chronic ulceration of the leg, *Surgery (Oxford)*. 37 (2019) 88–92. <https://doi.org/10.1016/j.mpsur.2018.12.009>.
- [45] H.S. Kim, X. Sun, J.-H. Lee, H.-W. Kim, X. Fu, K.W. Leong, Advanced drug delivery systems and artificial skin grafts for skin wound healing, *Advanced Drug Delivery Reviews*. 146 (2019) 209–239. <https://doi.org/10.1016/j.addr.2018.12.014>.
- [46] L.M. Morton, T.J. Phillips, Wound healing and treating wounds, *Journal of the American Academy of Dermatology*. 74 (2016) 589–605. <https://doi.org/10.1016/j.jaad.2015.08.068>.
- [47] R.G. Frykberg, J. Banks, Challenges in the Treatment of Chronic Wounds, *Advances in Wound Care*. 4 (2015) 560–582. <https://doi.org/10.1089/wound.2015.0635>.
- [48] S. Saghazadeh, C. Rinoldi, M. Schot, S.S. Kashaf, F. Sharifi, E. Jalilian, K. Nuutila, G. Giatsidis, P. Mostafalu, H. Derakhshandeh, K. Yue, W. Swieszkowski, A. Memic, A. Tamayol, A. Khademhosseini, Drug delivery systems and materials for wound healing applications, *Advanced Drug Delivery Reviews*. 127 (2018) 138–166. <https://doi.org/10.1016/j.addr.2018.04.008>.
- [49] M.F.P. Graça, S.P. Miguel, C.S.D. Cabral, I.J. Correia, Hyaluronic acid—Based wound dressings: A review, *Carbohydrate Polymers*. 241 (2020) 1–17. <https://doi.org/10.1016/j.carbpol.2020.116364>.
- [50] L.J. Cook, T. Kovacs, Novel devices for implant-based breast reconstruction: is the use of meshes to support the lower pole justified in terms of benefits? A review of the evidence, *Ecancer*. 12 (2018) 1–16. <https://doi.org/10.3332/ecancer.2018.796>.
- [51] S. Todros, P.G. Pavan, A.N. Natali, Biomechanical properties of synthetic surgical meshes for pelvic prolapse repair, *Journal of the Mechanical Behavior of Biomedical Materials*. 55 (2016) 271–285. <https://doi.org/10.1016/j.jmbbm.2015.10.024>.
- [52] Upsilon™ Y-Mesh & Colpassist™ Vaginal Positioning Device, Boston Scientific-, Boston Scientific. (n.d.). <https://www.bostonscientific.com/en-US/products/pelvic-floor-reconstruction/upsylon-y-mesh.html> (accessed July 7, 2020).
- [53] GORE-TEX® Soft Tissue Patch, Gore Medical., Gore Medical. (n.d.). <https://www.goremedical.com/products/stp> (accessed July 7, 2020).
- [54] TiLOOP® Bra Pocket, Pfm Medical., Pfm Medical. (n.d.). https://www.pfmmedical.com/productcatalogue/mesh_implants_breast_surgery/tiloopr_bra_pocket/index.html (accessed July 7, 2020).

- [55] TIGR® Matrix long-term resorbable mesh, Novus Scientific., Novus Scientific. (n.d.). <https://novusscientific.com/row/products/tigr-matrix/> (accessed July 7, 2020).
- [56] M. Mir, M.N. Ali, A. Barakullah, A. Gulzar, M. Arshad, S. Fatima, M. Asad, Synthetic polymeric biomaterials for wound healing: a review, *Prog Biomater.* 7 (2018) 1–21. <https://doi.org/10.1007/s40204-018-0083-4>.
- [57] Dermagraft, Dermagraft., Dermagraft. (n.d.). <https://dermagraft.com/why-choose-dermagraft/> (accessed July 8, 2020).
- [58] L. Alrubaiy, K.K. Al-Rubaiy, Skin Substitutes: A Brief Review of Types and Clinical Applications, *Oman Med J.* 24 (2009) 4–6. <https://doi.org/10.5001/omj.2009.2>.
- [59] Cytoflex® Tefguard®, Unicare Biomedical., Unicare Biomedical. (n.d.). https://www.unicarebiomedical.com/dental-supplies/cytoflex_ti_enforced.html (accessed June 15, 2020).
- [60] GUIDOR Matrix Barrier, Sunstar Group., Sunstar Group. (n.d.). <https://www.sunstar.com/healthy-thinking/guidor/> (accessed July 7, 2020).
- [61] Geistlich Bio-Gide®, Geistlich Pharma., Geistlich Pharma. (n.d.). <https://www.geistlich-pharma.com/en/dental/membranes/geistlich-bio-gide/user-benefits/> (accessed July 10, 2020).
- [62] U. Klinge, B. Klosterhalfen, Mesh implants for hernia repair: an update, *Expert Review of Medical Devices.* 15 (2018) 735–746. <https://doi.org/10.1080/17434440.2018.1529565>.
- [63] Y. Bachour, C.A. Bargon, C.J.M. de Blok, J.C.F. Ket, M.J.P.F. Ritt, F.B. Niessen, Risk factors for developing capsular contracture in women after breast implant surgery: A systematic review of the literature, *Journal of Plastic, Reconstructive & Aesthetic Surgery.* 71 (2018) 29–48. <https://doi.org/10.1016/j.bjps.2018.05.022>.
- [64] M.E. Falagas, S. Velakoulis, C. Iavazzo, S. Athanasiou, Mesh-related infections after pelvic organ prolapse repair surgery, *European Journal of Obstetrics & Gynecology and Reproductive Biology.* 134 (2007) 147–156. <https://doi.org/10.1016/j.ejogrb.2007.02.024>.
- [65] Y.-K. Wu, N.-C. Cheng, C.-M. Cheng, Biofilms in Chronic Wounds: Pathogenesis and Diagnosis, *Trends in Biotechnology.* 37 (2019) 505–517. <https://doi.org/10.1016/j.tibtech.2018.10.011>.
- [66] P. Chadwick, K. Ousey, Bacterial-binding dressings in the management of wound healing and infection prevention: a narrative review, *J Wound Care.* 28 (2019) 370–382. <https://doi.org/10.12968/jowc.2019.28.6.370>.
- [67] Mori da Cunha, M.G.M.C., Hympanova, L., Rynkevic, R., Mes, T., Bosman, A.W., Deprest, J., Biomechanical Behaviour and Biocompatibility of Ureidopyrimidinone-Polycarbonate Electrospun and Polypropylene Meshes in a Hernia Repair in Rabbits, *Materials.* 12 (2019) 1174. <https://doi.org/10.3390/ma12071174>.
- [68] B. Chen, B. Dave, Challenges and Future Prospects for Tissue Engineering in Female Pelvic Medicine and Reconstructive Surgery, *Curr Urol Rep.* 15 (2014) 425. <https://doi.org/10.1007/s11934-014-0425-2>.
- [69] Y.D. Rakhmatia, Y. Ayukawa, A. Furuhashi, K. Koyano, Current barrier membranes: Titanium mesh and other membranes for guided bone regeneration in dental applications, *Journal of Prosthodontic Research.* 57 (2013) 3–14. <https://doi.org/10.1016/j.jpor.2012.12.001>.
- [70] L.-M. Zhu, Mesh implants: An overview of crucial mesh parameters, *WJGS.* 7 (2015) 226–237. <https://doi.org/10.4240/wjgs.v7.i10.226>.
- [71] B. Watson, J. Roberts, B. Dobbs, R. Roberts, Is inguinal hernia mesh safe? A prospective study, *ANZ Journal of Surgery.* 90 (2020) 538–541. <https://doi.org/10.1111/ans.15518>.
- [72] FDA Executive summary, Surgical mehs for treatment of women with pelvic organ prolapse and stress urinary incontinence, (2011). <https://www.tvt-messed-up-mesh.org.uk/pdfs/fda-meeting-8-9th-sept-2011.pdf> (accessed July 10, 2020).
- [73] M. Dieterich, S. Paepke, K. Zwiefel, H. Dieterich, J. Blohmer, A. Faridi, E. Klein, B. Gerber, C. Nestle-Kraemling, Implant-Based Breast Reconstruction Using a Titanium-Coated

- Polypropylene Mesh (TiLOOP Bra): A Multicenter Study of 231 Cases, *Plastic and Reconstructive Surgery*. 132 (2013) 8e–19e. <https://doi.org/10.1097/PRS.0b013e318290f8a0>.
- [74] S.R. Evelhoch, Biofilm and Chronic Nonhealing Wound Infections, *Surgical Clinics of North America*. 100 (2020) 727–732. <https://doi.org/10.1016/j.suc.2020.05.004>.
- [75] G. Lim, G.-H. Lin, A. Monje, H.-L. Chan, H.-L. Wang, Wound Healing Complications Following Guided Bone Regeneration for Ridge Augmentation: A Systematic Review and Meta-Analysis, *Int J Oral Maxillofac Implants*. 33 (2018) 51–50. <https://doi.org/10.11607/jomi.5581>.
- [76] F.J. O'Brien, Biomaterials & scaffolds for tissue engineering, *Materials Today*. 14 (2011) 88–95. [https://doi.org/10.1016/S1369-7021\(11\)70058-X](https://doi.org/10.1016/S1369-7021(11)70058-X).
- [77] C. Eichler, C. Schulz, F. Thangarajah, W. Malter, M. Warm, K. Brunnert, A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery, *Anticancer Res*. 39 (2019) 2599–2605. <https://doi.org/10.21873/anticancer.13383>.
- [78] H.A. Maddah, Polypropylene as a Promising Plastic: A Review, *American Journal of Polymer Science*. 6 (2016) 1–11. <https://doi.org/DOI:10.5923/j.ajps.20160601.01>.
- [79] Q. Zhao, Y. Liu, H. Müller-Steinhagen, G. Liu, Graded Ni–P–PTFE coatings and their potential applications, *Surface and Coatings Technology*. 155 (2002) 279–284. [https://doi.org/10.1016/S0257-8972\(02\)00116-0](https://doi.org/10.1016/S0257-8972(02)00116-0).
- [80] W. Liu, X. Tian, P. Cui, Y. Li, K. Zheng, Y. Yang, Preparation and characterization of PET/silica nanocomposites, *Journal of Applied Polymer Science*. 91 (2004) 1229–1232. <https://doi.org/10.1002/app.13284>.
- [81] H. Koizumi, Y. Takeuchi, H. Imai, T. Kawai, T. Yoneyama, Application of titanium and titanium alloys to fixed dental prostheses, *Journal of Prosthodontic Research*. 63 (2019) 266–270. <https://doi.org/10.1016/j.jpor.2019.04.011>.
- [82] K.J. Jem, B. Tan, The development and challenges of poly (lactic acid) and poly (glycolic acid), *Advanced Industrial and Engineering Polymer Research*. 3 (2020) 60–70. <https://doi.org/10.1016/j.aiepr.2020.01.002>.
- [83] S. Roman, A. Mangera, N.I. Osman, A.J. Bullock, C.R. Chapple, S. MacNeil, Developing a tissue engineered repair material for treatment of stress urinary incontinence and pelvic organ prolapse-which cell source?: Which Cell Source?, *Neurourol. Urodynam*. 33 (2014) 531–537. <https://doi.org/10.1002/nau.22443>.
- [84] M. Mir, N. Ahmed, A. ur Rehman, Recent applications of PLGA based nanostructures in drug delivery, *Colloids and Surfaces B: Biointerfaces*. 159 (2017) 217–231. <https://doi.org/10.1016/j.colsurfb.2017.07.038>.
- [85] C. Choipang, P. Chuysinuan, O. Suwantong, P. Ekabutr, P. Supaphol, Hydrogel wound dressings loaded with PLGA/ciprofloxacin hydrochloride nanoparticles for use on pressure ulcers, *Journal of Drug Delivery Science and Technology*. 47 (2018) 106–114. <https://doi.org/10.1016/j.jddst.2018.06.025>.
- [86] L.P. de Melo, G.V. Salmoria, E.A. Fancello, C.R. de M. Roesler, Effect of Injection Molding Melt Temperatures on PLGA Craniofacial Plate Properties during In Vitro Degradation, *International Journal of Biomaterials*. 2017 (2017) 1–12. <https://doi.org/10.1155/2017/1256537>.
- [87] M.A. Woodruff, D.W. Hutmacher, The return of a forgotten polymer—Polycaprolactone in the 21st century, *Progress in Polymer Science*. 35 (2010) 1217–1256. <https://doi.org/10.1016/j.progpolymsci.2010.04.002>.
- [88] S.A. Shah, M. Sohail, S. Khan, M.U. Minhas, M. de Matas, V. Sikstone, Z. Hussain, M. Abbasi, M. Kousar, Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review, *International Journal of Biological Macromolecules*. 139 (2019) 975–993. <https://doi.org/10.1016/j.ijbiomac.2019.08.007>.

- [89] E. Leikina, M.V. Merts, N. Kuznetsova, S. Leikin, Type I collagen is thermally unstable at body temperature, *Proceedings of the National Academy of Sciences*. 99 (2002) 1314–1318. <https://doi.org/10.1073/pnas.032307099>.
- [90] C.H. Lee, A. Singla, Y. Lee, Biomedical applications of collagen, *International Journal of Pharmaceutics*. 221 (2001) 1–22. [https://doi.org/10.1016/S0378-5173\(01\)00691-3](https://doi.org/10.1016/S0378-5173(01)00691-3).
- [91] E. Szymańska, K. Winnicka, Stability of Chitosan—A Challenge for Pharmaceutical and Biomedical Applications, *Mar Drugs*. 13 (2015) 1819–1846. <https://doi.org/10.3390/md13041819>.
- [92] D. Ren, H. Yi, W. Wang, X. Ma, The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation, *Carbohydrate Research*. 340 (2005) 2403–2410. <https://doi.org/10.1016/j.carres.2005.07.022>.
- [93] E. Axibal, M. Brown, Surgical Dressings and Novel Skin Substitutes, *Dermatologic Clinics*. 37 (2019) 349–366. <https://doi.org/10.1016/j.det.2019.03.005>.
- [94] S. Jana, M.K. Trivedi, R.M. Tallapragada, A. Branton, D. Trivedi, G. Nayak, R. Mishra, Characterization of Physicochemical and Thermal Properties of Chitosan And Sodium Alginate after Biofield Treatment, *Pharmaceutica Analytica Acta*. 6 (2015) 1–9. <http://dx.doi.org/10.4172/2153-2435.1000430>.
- [95] X. Hao, E. Silva, A. Manssonbroberg, K. Grinnemo, A. Siddiqui, G. Dellgren, E. Wardell, L. Brodin, D. Mooney, C. Sylven, Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction, *Cardiovascular Research*. 75 (2007) 178–185. <https://doi.org/10.1016/j.cardiores.2007.03.028>.
- [96] E. Wales, S. Holloway, The use of prosthetic mesh for abdominal wall repairs: A semi-systematic-literature review, *Int Wound J*. 16 (2019) 30–40. <https://doi.org/10.1111/iwj.12977>.
- [97] J. Domínguez-Robles, C. Mancinelli, E. Mancuso, I. García-Romero, B.F. Gilmore, L. Casettari, E. Larrañeta, D.A. Lamprou, 3D Printing of Drug-Loaded Thermoplastic Polyurethane Meshes: A Potential Material for Soft Tissue Reinforcement in Vaginal Surgery, *Pharmaceutics*. 12 (2020) 1–15. <https://doi.org/10.3390/pharmaceutics12010063>.
- [98] A. Haryńska, I. Gubanska, J. Kucinska-Lipka, H. Janik, Fabrication and Characterization of Flexible Medical-Grade TPU Filament for Fused Deposition Modeling 3DP Technology, *Polymers*. 10 (2018) 1–19. <https://doi.org/10.3390/polym10121304>.
- [99] Y. Bilsel, I. Abci, The search for ideal hernia repair; mesh materials and types, *International Journal of Surgery*. 10 (2012) 317–321. <https://doi.org/10.1016/j.ijisu.2012.05.002>.
- [100] J.Y.S. Kim, A.S. Mlodinow, What's New in Acellular Dermal Matrix and Soft-Tissue Support for Prosthetic Breast Reconstruction:, *Plastic and Reconstructive Surgery*. 140 (2017) 30S–43S. <https://doi.org/10.1097/PRS.00000000000003950>.
- [101] J.R. Smith, D.A. Lamprou, Polymer coatings for biomedical applications: a review, *Transactions of the IMF*. 92 (2014) 9–19. <https://doi.org/10.1179/0020296713Z.000000000157>.
- [102] G.C. Ebersole, E.G. Buettmann, M.R. MacEwan, M.E. Tang, M.M. Frisella, B.D. Matthews, C.R. Deeken, Development of novel electrospun absorbable polycaprolactone (PCL) scaffolds for hernia repair applications, *Surg Endosc*. 26 (2012) 2717–2728. <https://doi.org/10.1007/s00464-012-2258-8>.
- [103] H. Xie, X. Chen, X. Shen, Y. He, W. Chen, Q. Luo, W. Ge, W. Yuan, X. Tang, D. Hou, D. Jiang, Q. Wang, Y. Liu, Q. Liu, K. Li, Preparation of chitosan-collagen-alginate composite dressing and its promoting effects on wound healing, *International Journal of Biological Macromolecules*. 107 (2018) 93–104. <https://doi.org/10.1016/j.ijbiomac.2017.08.142>.
- [104] S.-T. Li, H.-C. Chen, N.S. Lee, R. Ringshia, D. Yuen, A Comparative Study Of Zimmer BioMend® And BioMend® Extend™ Membranes Made At Two Different Manufacturing Facilities, (2013).
- [105] N. Udpa, S.R. Iyer, R. Rajoria, K.E. Breyer, H. Valentine, B. Singh, S.P. McDonough, B.N. Brown, L.J. Bonassar, Y. Gao, Effects of Chitosan Coatings on Polypropylene Mesh for

- Implantation in a Rat Abdominal Wall Model, *Tissue Engineering Part A*. 19 (2013) 2713–2723. <https://doi.org/10.1089/ten.tea.2012.0739>.
- [106] D.M. Faulk, R. Londono, M.T. Wolf, C.A. Ranallo, C.A. Carruthers, J.D. Wildemann, C.L. Dearth, S.F. Badylak, ECM hydrogel coating mitigates the chronic inflammatory response to polypropylene mesh, *Biomaterials*. 35 (2014) 8585–8595. <https://doi.org/10.1016/j.biomaterials.2014.06.057>.
- [107] P.L. Dwyer, Evolution of biological and synthetic grafts in reconstructive pelvic surgery, *Int Urogynecol J*. 17 (2006) 10–15. <https://doi.org/10.1007/s00192-006-0103-0>.
- [108] J. Bissoli, H. Bruschini, Scaffolds for pelvic floor prolapse: logical pathways, *International Journal of Biomaterials*. 2018 (2018).
- [109] M.E. Karlovsky, A.A. Thakre, A. Rastinehad, L. Kushner, G.H. Badlani, Biomaterials for pelvic floor reconstruction, *Urology*. 66 (2005) 469–475. <https://doi.org/10.1016/j.urology.2005.03.006>.
- [110] M.J. Jeon, S.W. Bai, Use of grafts in pelvic reconstructive surgery, *Yonsei Medical Journal*. 48 (2007) 147–156.
- [111] L.W. Kleiner, J.C. Wright, Y. Wang, Evolution of implantable and insertable drug delivery systems, *Journal of Controlled Release*. 181 (2014) 1–10. <https://doi.org/10.1016/j.jconrel.2014.02.006>.
- [112] Combating Antibiotic Resistance, U.S. Food and Drug Administration., U.S. Food and Drug Administration. (2019). <https://www.fda.gov/consumers/consumer-updates/combating-antibiotic-resistance> (accessed June 9, 2020).
- [113] Rifampicin, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf (accessed June 9, 2020).
- [114] J. Reinbold, T. Hierlemann, L. Urich, A.-K. Uhde, I. Müller, T. Weindl, U. Vogel, C. Schlensak, H.-P. Wendel, S. Krajewski, Biodegradable rifampicin-releasing coating of surgical meshes for the prevention of bacterial infections, *DDDT*. Volume 11 (2017) 2753–2762. <https://doi.org/10.2147/DDDT.S138510>.
- [115] E.M. Francisco, Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling potentially long-lasting side effects, *European Medicines Agency., European Medicines Agency*. (2018). <https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review> (accessed June 9, 2020).
- [116] O. Guillaume, J.-P. Lavigne, O. Lefranc, B. Nottelet, J. Coudane, X. Garric, New antibiotic-eluting mesh used for soft tissue reinforcement, *Acta Biomaterialia*. 7 (2011) 3390–3397. <https://doi.org/10.1016/j.actbio.2011.05.009>.
- [117] W. Florjanski, S. Orzeszek, A. Olchowy, N. Grychowska, W. Wieckiewicz, A. Malysa, J. Smardz, M. Wieckiewicz, Modifications of Polymeric Membranes Used in Guided Tissue and Bone Regeneration, *Polymers*. 11 (2019) 1–11. <https://doi.org/10.3390/polym11050782>.
- [118] S. Ma, A. Adayi, Z. Liu, M. Li, M. Wu, L. Xiao, Y. Sun, Q. Cai, X. Yang, X. Zhang, P. Gao, Asymmetric Collagen/chitosan Membrane Containing Minocycline-loaded Chitosan Nanoparticles for Guided Bone Regeneration, *Sci Rep*. 6 (2016) 1–10. <https://doi.org/10.1038/srep31822>.
- [119] S.M. Dizaj, F. Lotfipour, M. Barzegar-Jalali, M.H. Zarrintan, K. Adibkia, Antimicrobial activity of the metals and metal oxide nanoparticles, *Materials Science and Engineering: C*. 44 (2014) 278–284. <https://doi.org/10.1016/j.msec.2014.08.031>.
- [120] Z. Muwaffak, A. Goyanes, V. Clark, A.W. Basit, S.T. Hilton, S. Gaisford, Patient-specific 3D scanned and 3D printed antimicrobial polycaprolactone wound dressings, *International Journal of Pharmaceutics*. 527 (2017) 161–170. <https://doi.org/10.1016/j.ijpharm.2017.04.077>.
- [121] P. Chen, Z. Wu, A. Leung, X. Chen, E. Landao-Bassonga, J. Gao, L. Chen, M. Zheng, F. Yao, H. Yang, L. Lidgren, B. Allan, Y. Liu, T. Wang, M. Zheng, Fabrication of a silver nanoparticle-

- coated collagen membrane with anti-bacterial and anti-inflammatory activities for guided bone regeneration, *Biomed. Mater.* 13 (2018) 1–14. <https://doi.org/10.1088/1748-605X/aae15b>.
- [122] L. Marques, G. Martinez, É. Guidelli, J. Tamashiro, R. Segato, S.L.M. Payão, O. Baffa, A. Kinoshita, Performance on Bone Regeneration of a Silver Nanoparticle Delivery System Based on Natural Rubber Membrane NRL-AgNP, *Coatings*. 10 (2020) 1–15. <https://doi.org/10.3390/coatings10040323>.
- [123] B. Pérez-Köhler, M. Fernández-Gutiérrez, G. Pascual, F. García-Moreno, J. San Román, J.M. Bellón, In vitro assessment of an antibacterial quaternary ammonium-based polymer loaded with chlorhexidine for the coating of polypropylene prosthetic meshes, *Hernia*. 20 (2016) 869–878. <https://doi.org/10.1007/s10029-016-1537-z>.
- [124] B.S. Inoue, S. Streit, A.L. dos Santos Schneider, M.M. Meier, Bioactive bacterial cellulose membrane with prolonged release of chlorhexidine for dental medical application, *International Journal of Biological Macromolecules*. 148 (2020) 1098–1108. <https://doi.org/10.1016/j.ijbiomac.2020.01.036>.
- [125] FDA Drug Safety Communication: FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-allergic-reactions-skin-antiseptic> (accessed June 10, 2020).
- [126] T. Wang, X.-K. Zhu, X.-T. Xue, D.-Y. Wu, Hydrogel sheets of chitosan, honey and gelatin as burn wound dressings, *Carbohydrate Polymers*. 88 (2012) 75–83. <https://doi.org/10.1016/j.carbpol.2011.11.069>.
- [127] E. Mancuso, C. Tonda-Turo, C. Ceresa, V. Pensabene, S.D. Connell, L. Fracchia, P. Gentile, Potential of Manuka Honey as a Natural Polyelectrolyte to Develop Biomimetic Nanostructured Meshes With Antimicrobial Properties, *Front. Bioeng. Biotechnol.* 7 (2019) 1–13. <https://doi.org/10.3389/fbioe.2019.00344>.
- [128] R.E. Jung, R. Glauser, P. Schärer, C.H.F. Hämmerle, H.F. Sailer, F.E. Weber, Effect of rhBMP-2 on guided bone regeneration in humans: A randomized, controlled clinical and histomorphometric study, *Clinical Oral Implants Research*. 14 (2003) 556–568. <https://doi.org/10.1034/j.1600-0501.2003.00921.x>.
- [129] M. Ansarizadeh, S. Mashayekhan, M. Saadatmand, Fabrication, modeling and optimization of lyophilized advanced platelet rich fibrin in combination with collagen-chitosan as a guided bone regeneration membrane, *International Journal of Biological Macromolecules*. 125 (2019) 383–391. <https://doi.org/10.1016/j.ijbiomac.2018.12.078>.
- [130] Y. Wang, Z. Cao, R. Cheng, M. Qin, D. Zhang, L. Deng, X. Chen, W. Cui, Immunomodulated electrospun fibrous scaffolds via bFGF camouflage for pelvic regeneration, *Applied Materials Today*. 15 (2019) 570–581. <https://doi.org/10.1016/j.apmt.2019.04.005>.
- [131] C. Brown, J. Finch, Which mesh for hernia repair?, *Annals*. 92 (2010) 272–278. <https://doi.org/10.1308/003588410X12664192076296>.
- [132] R. Murugan, S. Ramakrishna, Design Strategies of Tissue Engineering Scaffolds with Controlled Fiber Orientation, *Tissue Engineering*. 13 (2007) 1845–1866. <https://doi.org/10.1089/ten.2006.0078>.
- [133] S. Chen, R. Li, X. Li, J. Xie, Electrospinning: An enabling nanotechnology platform for drug delivery and regenerative medicine, *Advanced Drug Delivery Reviews*. 132 (2018) 188–213. <https://doi.org/10.1016/j.addr.2018.05.001>.
- [134] A. Mohammed, A. Elshaer, P. Sareh, M. Elsayed, H. Hassanin, Additive Manufacturing Technologies for Drug Delivery Applications, *International Journal of Pharmaceutics*. 580 (2020) 1–24. <https://doi.org/10.1016/j.ijpharm.2020.119245>.
- [135] R. Zelkó, D.A. Lamprou, I. Sebe, Recent Development of Electrospinning for Drug Delivery, *Pharmaceutics*. 12 (2020) 1–5. <https://doi.org/10.3390/pharmaceutics12010005>.

- [136] M. Liu, Y. Zhang, S. Sun, A.R. Khan, J. Ji, M. Yang, G. Zhai, Recent advances in electrospun for drug delivery purpose, *Journal of Drug Targeting*. 27 (2019) 270–282. <https://doi.org/10.1080/1061186X.2018.1481413>.
- [137] H. Lian, Z. Meng, Melt electrospinning vs. solution electrospinning: A comparative study of drug-loaded poly (ϵ -caprolactone) fibres, *Materials Science and Engineering: C*. 74 (2017) 117–123. <https://doi.org/10.1016/j.msec.2017.02.024>.
- [138] T.J. Sill, H.A. von Recum, Electrospinning: Applications in drug delivery and tissue engineering, *Biomaterials*. 29 (2008) 1989–2006. <https://doi.org/10.1016/j.biomaterials.2008.01.011>.
- [139] I.J. Hall Barrientos, E. Paladino, P. Szabó, S. Brozio, P.J. Hall, C.I. Oseghale, M.K. Passarelli, S.J. Moug, R.A. Black, C.G. Wilson, R. Zelkó, D.A. Lamprou, Electrospun collagen-based nanofibres: A sustainable material for improved antibiotic utilisation in tissue engineering applications, *International Journal of Pharmaceutics*. 531 (2017) 67–79. <https://doi.org/10.1016/j.ijpharm.2017.08.071>.
- [140] N. Nikmaram, S. Roohinejad, S. Hashemi, M. Koubaa, F.J. Barba, A. Abbaspourrad, R. Greiner, Emulsion-based systems for fabrication of electrospun nanofibers: food, pharmaceutical and biomedical applications, *RSC Adv*. 7 (2017) 28951–28964. <https://doi.org/10.1039/C7RA00179G>.
- [141] I.J. Hall Barrientos, E. Paladino, S. Brozio, M.K. Passarelli, S. Moug, R.A. Black, C.G. Wilson, D.A. Lamprou, Fabrication and characterisation of drug-loaded electrospun polymeric nanofibers for controlled release in hernia repair, *International Journal of Pharmaceutics*. 517 (2017) 329–337. <https://doi.org/10.1016/j.ijpharm.2016.12.022>.
- [142] I. Hall Barrientos, G. MacKenzie, C. Wilson, D. Lamprou, P. Coats, Biological Performance of Electrospun Polymer Fibres, *Materials*. 12 (2019) 363. <https://doi.org/10.3390/ma12030363>.
- [143] 5 Things to Know About Triclosan, U. S. Food and Drug Administration., U.S. Food and Drug Administration. (2019). <https://www.fda.gov/consumers/consumer-updates/5-things-know-about-triclosan> (accessed June 16, 2020).
- [144] A. Khalf, S.V. Madihally, Recent advances in multiaxial electrospinning for drug delivery, *European Journal of Pharmaceutics and Biopharmaceutics*. 112 (2017) 1–17. <https://doi.org/10.1016/j.ejpb.2016.11.010>.
- [145] P. He, Q. Zhong, Y. Ge, Z. Guo, J. Tian, Y. Zhou, S. Ding, H. Li, C. Zhou, Dual drug loaded coaxial electrospun PLGA/PVP fiber for guided tissue regeneration under control of infection, *Materials Science and Engineering: C*. 90 (2018) 549–556. <https://doi.org/10.1016/j.msec.2018.04.014>.
- [146] G. Prado-Prone, P. Silva-Bermudez, A. Almaguer-Flores, J.A. García-Macedo, V.I. García, S.E. Rodil, C. Ibarra, C. Velasquillo, Enhanced antibacterial nanocomposite mats by coaxial electrospinning of polycaprolactone fibers loaded with Zn-based nanoparticles, *Nanomedicine: Nanotechnology, Biology and Medicine*. 14 (2018) 1695–1706. <https://doi.org/10.1016/j.nano.2018.04.005>.
- [147] S.G. Hansen, M.B. Taskin, M. Chen, L. Wogensen, J. Vinge Nygaard, S.M. Axelsen, Electrospun nanofiber mesh with fibroblast growth factor and stem cells for pelvic floor repair, *J. Biomed. Mater. Res.* (2019) jbm.b.34364. <https://doi.org/10.1002/jbm.b.34364>.
- [148] C. Zhang, F. Feng, H. Zhang, Emulsion electrospinning: Fundamentals, food applications and prospects, *Trends in Food Science & Technology*. 80 (2018) 175–186. <https://doi.org/10.1016/j.tifs.2018.08.005>.
- [149] B. Pant, M. Park, S.-J. Park, Drug Delivery Applications of Core-Sheath Nanofibers Prepared by Coaxial Electrospinning: A Review, *Pharmaceutics*. 11 (2019) 1–21. <https://doi.org/10.3390/pharmaceutics11070305>.

- [150] R. Jain, S. Shetty, K.S. Yadav, Unfolding the electrospinning potential of biopolymers for preparation of nanofibers, *Journal of Drug Delivery Science and Technology*. 57 (2020) 1–15. <https://doi.org/10.1016/j.jddst.2020.101604>.
- [151] N. Mangır, A.J. Bullock, S. Roman, N. Osman, C. Chapple, S. MacNeil, Production of ascorbic acid releasing biomaterials for pelvic floor repair, *Acta Biomaterialia*. 29 (2016) 188–197. <https://doi.org/10.1016/j.actbio.2015.10.019>.
- [152] M. Doostmohammadi, H. Forootanfar, S. Ramakrishna, Regenerative medicine and drug delivery: Progress via electrospun biomaterials, *Materials Science and Engineering: C*. 109 (2020) 1–21. <https://doi.org/10.1016/j.msec.2019.110521>.
- [153] P. Szymczyk-Ziółkowska, M.B. Łabowska, J. Detyna, I. Michalak, P. Gruber, A review of fabrication polymer scaffolds for biomedical applications using additive manufacturing techniques, *Biocybernetics and Biomedical Engineering*. 40 (2020) 624–638. <https://doi.org/10.1016/j.bbe.2020.01.015>.
- [154] S.M. Giannitelli, P. Mozetic, M. Trombetta, A. Rainer, Combined additive manufacturing approaches in tissue engineering, *Acta Biomaterialia*. 24 (2015) 1–11. <https://doi.org/10.1016/j.actbio.2015.06.032>.
- [155] S. Miramini, K.L. Fegan, N.C. Green, D.M. Espino, L. Zhang, L.E.J. Thomas-Seale, The status and challenges of replicating the mechanical properties of connective tissues using additive manufacturing, *Journal of the Mechanical Behavior of Biomedical Materials*. 103 (2020) 1–22. <https://doi.org/10.1016/j.jmbbm.2019.103544>.
- [156] G. Brunello, S. Sivoletta, R. Meneghello, L. Ferroni, C. Gardin, A. Piattelli, B. Zavan, E. Bressan, Powder-based 3D printing for bone tissue engineering, *Biotechnology Advances*. 34 (2016) 740–753. <https://doi.org/10.1016/j.biotechadv.2016.03.009>.
- [157] M. Hassan, K. Dave, R. Chandrawati, F. Dehghani, V.G. Gomes, 3D printing of biopolymer nanocomposites for tissue engineering: Nanomaterials, processing and structure-function relation, *European Polymer Journal*. 121 (2019) 1–15. <https://doi.org/10.1016/j.eurpolymj.2019.109340>.
- [158] L. Moroni, T. Boland, J.A. Burdick, C. De Maria, B. Derby, G. Forgacs, J. Groll, Q. Li, J. Malda, V.A. Mironov, C. Mota, M. Nakamura, W. Shu, S. Takeuchi, T.B.F. Woodfield, T. Xu, J.J. Yoo, G. Vozzi, Biofabrication: A Guide to Technology and Terminology, *Trends in Biotechnology*. 36 (2018) 384–402. <https://doi.org/10.1016/j.tibtech.2017.10.015>.
- [159] Z. Gu, J. Fu, H. Lin, Y. He, Development of 3D bioprinting: From printing methods to biomedical applications, *Asian Journal of Pharmaceutical Sciences*. (2019) 1–29. <https://doi.org/10.1016/j.ajps.2019.11.003>.
- [160] M. Stanković, H.W. Frijlink, W.L.J. Hinrichs, Polymeric formulations for drug release prepared by hot melt extrusion: application and characterization, *Drug Discovery Today*. 20 (2015) 812–823. <https://doi.org/10.1016/j.drudis.2015.01.012>.
- [161] E. Mathew, J. Domínguez-Robles, S.A. Stewart, E. Mancuso, K. O'Donnell, E. Larrañeta, D.A. Lamprou, Fused Deposition Modeling as an Effective Tool for Anti-Infective Dialysis Catheter Fabrication, *ACS Biomater. Sci. Eng.* 5 (2019) 6300–6310. <https://doi.org/10.1021/acsbiomaterials.9b01185>.
- [162] M. Mobaraki, M. Ghaffari, A. Yazdanpanah, Y. Luo, D.K. Mills, Bioinks and bioprinting: A focused review, *Bioprinting*. 18 (2020) 1–16. <https://doi.org/10.1016/j.bprint.2020.e00080>.
- [163] N. Qamar, N. Abbas, M. Irfan, A. Hussain, M.S. Arshad, S. Latif, F. Mehmood, M.U. Ghori, Personalized 3D printed ciprofloxacin impregnated meshes for the management of hernia, *Journal of Drug Delivery Science and Technology*. 53 (2019) 1–8. <https://doi.org/10.1016/j.jddst.2019.101164>.
- [164] W. Baek, M.S. Kim, D.B. Park, O.Y. Joo, W.J. Lee, T.S. Roh, H.-J. Sung, Three-Dimensionally Printed Breast Reconstruction Devices Facilitate Nanostructure Surface-Guided Healthy Lipogenesis, *ACS Biomater. Sci. Eng.* 5 (2019) 4962–4969. <https://doi.org/10.1021/acsbiomaterials.9b00985>.

- [165] J.-H. Shim, J.-Y. Won, S.-J. Sung, D.-H. Lim, W.-S. Yun, Y.-C. Jeon, J.-B. Huh, Comparative Efficacies of a 3D-Printed PCL/PLGA/ β -TCP Membrane and a Titanium Membrane for Guided Bone Regeneration in Beagle Dogs, *Polymers*. 7 (2015) 2061–2077. <https://doi.org/10.3390/polym7101500>.
- [166] S. Wang, Y. Xiong, J. Chen, A. Ghanem, Y. Wang, J. Yang, B. Sun, Three Dimensional Printing Bilayer Membrane Scaffold Promotes Wound Healing, *Front. Bioeng. Biotechnol.* 7 (2019) 1–11. <https://doi.org/10.3389/fbioe.2019.00348>.
- [167] F. Afghah, M. Ullah, J. Seyyed Monfared Zanjani, P. Akkuş Süt, O. Sen, M. Emanet, B. Saner Okan, M. Culha, Y. Menciloglu, M. Yildiz, B. Koc, 3D printing of silver-doped polycaprolactone-poly propylene succinate composite scaffolds for skin tissue engineering, *Biomed. Mater.* 15 (2020) 035015. <https://doi.org/10.1088/1748-605X/ab7417>.
- [168] P.D. Dalton, Melt electrowriting with additive manufacturing principles, *Current Opinion in Biomedical Engineering*. 2 (2017) 49–57. <https://doi.org/10.1016/j.cobme.2017.05.007>.
- [169] T.M. Robinson, D.W. Hutmacher, P.D. Dalton, The Next Frontier in Melt Electrospinning: Taming the Jet, *Adv. Funct. Mater.* 29 (2019) 1904664. <https://doi.org/10.1002/adfm.201904664>.
- [170] E. Hewitt, S. Mros, M. Mcconnell, J. Cabral, A. Ali, Melt-electrowriting with novel milk protein/PCL biomaterials for skin regeneration, *Biomed. Mater.* (2019) 1–16. <https://doi.org/10.1088/1748-605X/ab3344>.
- [171] N. Dubey, J.A. Ferreira, A. Dagherery, Z. Aytac, J. Malda, S.B. Bhaduri, M.C. Bottino, Highly Tunable Bioactive Fiber-Reinforced Hydrogel for Guided Bone Regeneration, *Acta Biomaterialia*. 113 (2020) 164–176. <https://doi.org/10.1016/j.actbio.2020.06.011>.
- [172] K. Paul, S. Darzi, G. Mcphee, M.D. Borgo, J.A. Werkmeister, C.E. Gargett, S. Mukherjee, 3D Bioprinted Endometrial Stem Cells on Melt Electrospun PCL Meshes for Pelvic Floor Application Promote Anti-Inflammatory Responses in Mice, *Social Science Research Network*, Rochester, NY, 2019. <https://papers.ssrn.com/abstract=3387674> (accessed November 8, 2019).
- [173] G. Habiboallah, Z. Mahdi, Z. Majid, S. Nasroallah, A.M. Taghavi, A. Forouzanfar, N. Arjmand, Enhancement of Gingival Wound Healing by Local Application of Silver Nanoparticles Periodontal Dressing Following Surgery: A Histological Assessment in Animal Model, *MRI*. 03 (2014) 128–138. <https://doi.org/10.4236/mri.2014.33016>.
- [174] S. García-Salinas, M. Evangelopoulos, E. Gámez-Herrera, M. Arruebo, S. Irusta, F. Taraballi, G. Mendoza, E. Tasciotti, Electrospun anti-inflammatory patch loaded with essential oils for wound healing, *International Journal of Pharmaceutics*. 577 (2020) 119067. <https://doi.org/10.1016/j.ijpharm.2020.119067>.
- [175] Urogynecologic Surgical Mesh Implants, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/implants-and-prosthetics/urogynecologic-surgical-mesh-implants> (accessed June 19, 2020).
- [176] FDA’s Activities: Urogynecologic Surgical Mesh, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/urogynecologic-surgical-mesh-implants/fdas-activities-urogynecologic-surgical-mesh> (accessed July 9, 2020).
- [177] Barber S., Surgical mesh implants, (2018).
- [178] Vaginal mesh surgery should be a last resort, National Health Service., National Health Service. (2018). <https://www.nhs.uk/news/medical-practice/vaginal-mesh-surgery-should-be-last-resort-says-nice/> (accessed June 19, 2020).
- [179] Medical devices: guidance for manufacturers on vigilance, GOV.UK., GOV.UK. (n.d.). <https://www.gov.uk/government/collections/medical-devices-guidance-for-manufacturers-on-vigilance> (accessed June 19, 2020).
- [180] Considerations about Surgical Mesh for SUI, U. S. Food and Drug Administration, U. S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/urogynecologic-surgical-mesh-implants/considerations-about-surgical-mesh-sui> (accessed July 9, 2020).

- [181] Lockhart K., Dunn D., Teo S., Ng J.Y., Dhillon M., Teo E., van Driel M.L., Comparing surgical groin hernia repair performed with or without mesh, *Cochrane Database of Systematic Reviews*. (2018) CD011517. <https://doi.org/10.1002/14651858.CD011517.pub2>.
- [182] Hernia Surgical Mesh Implants: Reporting Problems to the FDA, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2018). <https://www.fda.gov/medical-devices/hernia-surgical-mesh-implants/hernia-surgical-mesh-implants-reporting-problems-fda> (accessed July 9, 2020).
- [183] Antimicrobial dressings, National Institute for Health and Care., National Institute for Health and Care. (n.d.). <https://bnf.nice.org.uk/wound-management/antimicrobial-dressings.html> (accessed July 11, 2020).
- [184] Honey dressings, National Institute for Health and Care., National Institute for Health and Care. (n.d.). <https://bnf.nice.org.uk/wound-management/honey-dressings.html> (accessed July 11, 2020).
- [185] C. Brouillard, A.-C. Bursztejn, C. Latache, J.-F. Cuny, F. Truchetet, J.-P. Goullé, J.-L. Schmutz, Silver absorption and toxicity evaluation of silver wound dressings in 40 patients with chronic wounds, *Journal of the European Academy of Dermatology and Venereology*. 32 (2018) 2295–2299. <https://doi.org/10.1111/jdv.15055>.
- [186] Silver dressings, National Institute for Health and Care., National Institute for Health and Care. (n.d.). <https://bnf.nice.org.uk/wound-management/silver-dressings.html> (accessed July 11, 2020).
- [187] Statement by FDA Commissioner Scott Gottlieb, M.D., on FDA ushering in new era of 3D printing of medical products; provides guidance to manufacturers of medical devices, U. S. Food and Drug Administration., U. S. Food and Drug Administration. (2020). <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fda-ushering-new-era-3d-printing-medical-products> (accessed July 10, 2020).
- [188] Technical Considerations for Additive Manufactured Medical Devices - Guidance for Industry and Food and Drug Administration Staff, U. S. Food and Drug Administration., (2017).
- [189] FDA’s Role in 3D Printing, U. S. Food and Drug administration., U.S. Food and Drug Administration. (2019). <https://www.fda.gov/medical-devices/3d-printing-medical-devices/fdas-role-3d-printing> (accessed July 10, 2020).
- [190] R. Sathasivam, G. Bussa, Y. Viswanath, R.-B. Obuobi, T. Gill, A. Reddy, V. Shanmugam, A. Gilliam, P. Thambi, ‘Mesh hiatal hernioplasty’ versus ‘suture cruroplasty’ in laparoscopic para-oesophageal hernia surgery; a systematic review and meta-analysis, *Asian Journal of Surgery*. 42 (2019) 53–60. <https://doi.org/10.1016/j.asjsur.2018.05.001>.
- [191] N. Mangir, S. Roman, C.R. Chapple, S. MacNeil, Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation?, *World J Urol*. 38 (2020) 73–80. <https://doi.org/10.1007/s00345-019-02679-w>.